


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:07Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406193" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406193</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="a435140976" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406193</article-id><article-id pub-id-type="pmcid-ver">PMC12406193.1</article-id><article-id pub-id-type="pmcaid">12406193</article-id><article-id pub-id-type="pmcaiid">12406193</article-id><article-id pub-id-type="pmid">40801814</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c01421</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Affinity and
Selectivity of Protein&#8211;Ligand
Recognition: A Minor Chemical Modification Changes Carbonic Anhydrase
Binding Profile</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5896950</contrib-id><name name-style="western"><surname>Zak&#353;auskas</surname><given-names initials="A">Audrius</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5896955</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0919-7826</contrib-id><name name-style="western"><surname>Paketuryt&#279;-Latv&#279;</surname><given-names initials="V">Vaida</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7405552</contrib-id><name name-style="western"><surname>Janku&#773;nait&#279;</surname><given-names initials="A">Alberta</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5896966</contrib-id><name name-style="western"><surname>&#268;apkauskait&#279;</surname><given-names initials="E">Edita</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7405561</contrib-id><name name-style="western"><surname>Becart</surname><given-names initials="Y">Yann</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3121414</contrib-id><name name-style="western"><surname>Smirnov</surname><given-names initials="A">Alexey</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6355382</contrib-id><name name-style="western"><surname>Posp&#237;&#353;ilov&#225;</surname><given-names initials="K">Kl&#225;ra</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6488242</contrib-id><name name-style="western"><surname>Leitans</surname><given-names initials="J">Janis</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5370731</contrib-id><name name-style="western"><surname>Brynda</surname><given-names initials="J">Ji&#345;&#237;</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7620893</contrib-id><name name-style="western"><surname>Kazaks</surname><given-names initials="A">Andris</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4735671</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9924-9177</contrib-id><name name-style="western"><surname>Baranauskien&#279;</surname><given-names initials="L">Lina</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7153104</contrib-id><name name-style="western"><surname>Manakova</surname><given-names initials="E">Elena</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7153116</contrib-id><name name-style="western"><surname>Gra&#382;ulis</surname><given-names initials="S">Saulius</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath14" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3166487</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5427-0175</contrib-id><name name-style="western"><surname>Kairys</surname><given-names initials="V">Visvaldas</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath15" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1072908</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8421-9023</contrib-id><name name-style="western"><surname>Tars</surname><given-names initials="K">Kaspars</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath16" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6181732</contrib-id><name name-style="western"><surname>&#344;ez&#225;&#269;ov&#225;</surname><given-names initials="P">Pavl&#237;na</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath17" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">86887</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6178-6276</contrib-id><name name-style="western"><surname>Matulis</surname><given-names initials="D">Daumantas</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Biothermodynamics and Drug Design, Institute of Biotechnology,
Life Sciences Center</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">54694</institution-id><institution>Vilnius University</institution></institution-wrap>, <addr-line>Saul&#279;tekio al. 7</addr-line>, <city>Vilnius</city>
<postal-code>LT-10257</postal-code>, <country country="LT">Lithuania</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">89220</institution-id><institution>Institute
of Organic Chemistry and Biochemistry of the Czech Academy of Sciences</institution></institution-wrap>, <addr-line>Flemingovo n. 2</addr-line>, <city>Prague 6</city>
<postal-code>16610</postal-code>, <country country="CZ">Czech Republic</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">382968</institution-id><institution>Latvian
Biomedical Research and Study Centre</institution></institution-wrap>, <addr-line>Ratsupites 1 k-1</addr-line>, <city>Riga</city>
<postal-code>LV-1067</postal-code>, <country country="LV">Latvia</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Department
of Protein&#8722;DNA Interactions, Institute of Biotechnology, Life
Sciences Center</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">54694</institution-id><institution>Vilnius University</institution></institution-wrap>, <addr-line>Saul&#279;tekio al. 7</addr-line>, <city>Vilnius</city>
<postal-code>LT-10257</postal-code>, <country country="LT">Lithuania</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">Department
of Bioinformatics, Institute of Biotechnology, Life Sciences Center</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">54694</institution-id><institution>Vilnius University</institution></institution-wrap>, <addr-line>Saul&#279;tekio 7</addr-line>, <city>Vilnius</city>
<postal-code>LT-10257</postal-code>, <country country="LT">Lithuania</country>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="dept">Sector
of
Crystallography and Cheminformatics, Institute of Biotechnology, Life
Sciences Center</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">54694</institution-id><institution>Vilnius University</institution></institution-wrap>, <addr-line>Saul&#279;tekio al. 7</addr-line>, <city>Vilnius</city>
<postal-code>LT-10257</postal-code>, <country country="LT">Lithuania</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>daumantas.matulis@bti.vu.lt</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17752</fpage><lpage>17773</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2025</year></date><date date-type="online"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-13"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-13">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c01421.pdf"/><abstract><p>Discovery of small-molecule drugs relies on their strong
binding
affinity compared to nontarget proteins, thus possessing selectivity.
Minor chemical structure changes usually exhibit little change in
the compound efficacy, with rare exceptions. We developed a series
of nearly 50 <italic toggle="yes">ortho</italic>-substituted benzenesulfonamides
and experimentally measured their interactions with the 12 catalytically
active human carbonic anhydrase (CA) isozymes. Inhibitors were designed
using seven different substituent groups, including 4-<italic toggle="yes">sulfanyl</italic>-substituted 3-sulfamoyl benzoates and benzamides, 4-<italic toggle="yes">sulfinyl</italic>-substituted 3-sulfamoyl benzoates and benzamides, 4-<italic toggle="yes">sulfonyl</italic>-substituted 3-sulfamoyl benzoates and benzamides, and 4-amino-substituted
benzamides. The oxidation state of sulfur at the <italic toggle="yes">ortho</italic> position significantly influenced the compound&#8217;s affinity
for CAIX, a target for anticancer drugs, demonstrating affinities
hundreds of thousands of times stronger than related compounds. Coupled
with X-ray crystal structures and molecular docking, the relationship
between structure and thermodynamics offers insights into how small
changes in the structure lead to significant changes in affinity for
drug design.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c01421_0016.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c01421_0014.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>NextGenerationEU</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100031478</institution-id></institution-wrap></funding-source><award-id>LX22NPO5102</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>European Commission</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000780</institution-id></institution-wrap></funding-source><award-id>5.2.1.1.i.0/2/24/I/CFLA/001</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Lietuvos Mokslo Taryba</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004504</institution-id></institution-wrap></funding-source><award-id>S-MIP-22-35</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c01421</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c01421</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>f28983f0ab46ebf001a929d93aae52267d1d3764ccb4847616ddba8c2701d41c</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>A detailed understanding of protein&#8211;ligand
recognition is
an essential goal in small-molecule drug discovery.<xref rid="ref1" ref-type="bibr"/> Any drug-like chemical compound should bind the disease-related
target protein with sufficiently high affinity. Furthermore, the compound
must bind with high selectivity and thus not interact strongly with
other nontarget proteins whose inhibition or binding could cause undesired
side effects.<xref rid="ref2" ref-type="bibr"/> Rational design of such
compounds is complex because of the limited understanding of the underlying
energies of binding and how a compound recognizes and binds to the
target protein.</p><p>As a model system, we study sulfonamide compound
binding to human
carbonic anhydrases (CA), zinc-containing enzymes.<xref rid="ref3" ref-type="bibr"/> Humans have 12 catalytically active CA isozymes (EC 4.2.1.1).<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr"/>
</named-content> The enzyme catalyzes the reversible hydration of carbon dioxide
and has many essential physiological functions. Since these enzymes
function in pH and electrolyte homeostasis and regulation, many drugs
target CA isozymes to treat diseases like glaucoma, edema, obesity,
epilepsy, infertility, and cancer.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>&#8722;<xref rid="ref8" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref9" ref-type="bibr"/>
</named-content> Primary sulfonamides
are the most investigated CA inhibitors.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>&#8722;<xref rid="ref11" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref12" ref-type="bibr"/>
</named-content> Their amino
group binds directly to the catalytic zinc in the active site by forming
a coordination bond and inhibits the activity of all CA isozymes.
However, the binding affinity may be low or high and depends on small
details of each compound arrangement on the protein surface, possible
steric hindrances, or attraction due to hydrogen bonds or hydrophobic
interactions.<xref rid="ref13" ref-type="bibr"/>
</p><p>The 12 catalytically
active human CA isozymes have nearly identical
beta-sheet folds. Their active sites are highly similar in shape,
but several amino acids in the active site vary among the isozymes.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>&#8722;<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr"/>
</named-content> Because the differences in the active site amino acid composition
are small, it is difficult to design compounds that would bind one
isozyme with high affinity while all other isozymes with low affinity,
thus leading toward high selectivity for only one isozyme. The active
site of CAs is funnel-shaped and has hydrophobic and hydrophilic sides
for some isozymes. Differences in a few amino acids determine the
selectivity of inhibitors for particular isozymes. Introducing various
scaffolds on the aromatic sulfonamide ring targets unique residues
in the active site.<xref rid="ref17" ref-type="bibr"/> In most studies,
the tails are relatively distant from the sulfonamide group, resulting
in weak interactions with peripheral amino acids. The affinity profile
depended mostly on the substituents located close to the sulfonamide
headgroup.<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>&#8722;<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content> This is also dependent on the flexibility of the
substituents, which help adjust to the protein shape.</p><p>Depending
on the variation of the substituents while investigating
doubly substituted compounds,<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>&#8722;<xref rid="ref21" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref22" ref-type="bibr"/>
</named-content> several high-affinity compounds
exhibiting picomolar <italic toggle="yes">K</italic>
<sub>d</sub> were obtained
for CAVII, CAIX, CAXII, and CAXIV. A significant achievement was a <italic toggle="yes">LJ15-12</italic> compound that exhibited 0.08 pM intrinsic <italic toggle="yes">K</italic>
<sub>d</sub> for CAIX.<xref rid="ref20" ref-type="bibr"/> In
this study, we investigate the functional groups in the <italic toggle="yes">ortho</italic> position by varying 13 substituents from small methyl to bulky adamantyl.
Sulfinyl and amino substituents were also synthesized to examine the
influence of the linking atoms. Interestingly, the substitution of
only one atom, an addition of an oxygen atom in the <italic toggle="yes">ortho</italic> position, decreased compound affinity for nontarget isozymes by
a million-fold, significantly improving the selectivity, which is
one of the main goals in small-molecule drug discovery.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Organic Synthesis of Designed Compounds</title><p>The synthesis
of 2,5-disubstituted benzenesulfonamides was performed starting from
4-chloro-3-sulfamoylbenzoic acid <bold>1</bold> (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). Methyl ester <bold>2</bold> was obtained from 4-chloro-3-sulfamoylbenzoic acid <bold>1</bold> by reflux in methanol in the presence of a catalytic amount of sulfuric
acid. Amide <bold>3</bold> was synthesized by refluxing acid <bold>1</bold> with thionyl chloride in toluene and subsequent treatment,
the resulting anhydride with an appropriate amine, using as the base
excess of amine according to the procedure reported in ref <xref rid="ref21" ref-type="bibr" specific-use="ref-style=base-text"/>.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthesis of Methyl
4-Substituted-3-Sulfamoylbenzoates <bold>4a&#8211;d,
f&#8211;m</bold>, 4-Substituted 3-Sulfamoylbenzamides <bold>5a&#8211;d,
f, g, j&#8211;m</bold>, and 4-Amino-Substituted Benzamides <bold>6b, c, e</bold>
<xref rid="sch1-fn1" ref-type="fn"/>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c01421_0010.jpg"/><p>
<fn id="sch1-fn1"><label>a</label><p>Reagents and conditions:
(i)
RSH, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 &#176;C; (ii) H<sub>2</sub>SO<sub>4</sub>, MeOH, &#916;; (iii) (a) SOCl<sub>2</sub>, toluene,
&#916;, (b) RNH<sub>2</sub>, THF, 0 &#176;C; (iv) RNH<sub>2</sub>, 130 &#176;C; (v) RNH<sub>2</sub>, TEA, toluene, &#916;.</p></fn>
</p></fig><p>The synthesis of 4-substituted sulfamoylbenzoic acid
derivatives <bold>4a&#8211;d, f&#8211;m</bold> was achieved by aromatic
nucleophilic
substitution of the chlorine substituent with various thiols under
an inert atmosphere in dimethylformamide using potassium carbonate
as the base (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). All thiols were commercially available except cyclododecylthiol,
which was synthesized by subjecting cyclododecanone to reaction with
1,2-ethanedithiol and subsequent reduction of intermediate dithiolane
with <italic toggle="yes">n</italic>-butyllithium.<xref rid="ref23" ref-type="bibr"/>
</p><p>The 4-substituted 3-sulfamoylbenzamides <bold>5a</bold>&#8211;<bold>d</bold>, <bold>f</bold>, <bold>g</bold>, <bold>j&#8211;m</bold> were synthesized using the same reaction conditions as 4-sulfanyl-substituted
esters <bold>4a&#8211;d, f&#8211;m</bold>. Substitution of the chlorine
group with amines required harsher reaction conditions than thiols.
Therefore, 4-amino-substituted benzamides <bold>6b</bold> and <bold>c</bold> were synthesized by heating amide <bold>3</bold> over the
appropriate amine at 130 &#176;C. Compound <bold>6e</bold> was synthesized
by boiling amide <bold>3</bold> in toluene with 2 equiv of cyclooctylamine
and 2 equiv of triethylamine.</p><p>The oxidation of esters <bold>4a&#8211;d, h, i, k&#8211;m</bold> and benzamides <bold>5a</bold>, <bold>b</bold>, <bold>k&#8211;m</bold> to the sulfinyl and sulfonyl
compounds was performed using in situ
generated peracetic acid (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>). The reaction was carried out at room temperature
and produced 4-sulfinyl compounds <bold>7a, b, h, i, k&#8211;m</bold>, <bold>8a, b, k&#8211;m</bold>, and heating the reaction mixture
at 70 &#176;C yielded the corresponding 4-sulfonyl compounds <bold>9a&#8211;d, h, i, l, m, 10b,</bold> and <bold>k&#8211;m</bold>.</p><fig position="float" id="sch2" fig-type="scheme" orientation="portrait"><label>2</label><caption><title>Synthesis of Methyl 4-Sulfinyl-Substituted-3-Sulfamoyl Benzoates <bold>7a, b, h, i, k&#8211;m</bold>, <italic toggle="yes">N</italic>-Butyl-4-sulfinyl-Substituted-3-Sulfamoylbenzamides <bold>8a, b, k&#8211;m</bold>, Methyl 4-Sulfonyl-Substituted-3-Sulfamoylbenzoates <bold>9a-d, h, i, l, m,</bold> and <italic toggle="yes">N</italic>-Butyl-4-sulfonyl-Substituted-3-Sulfamoylbenzamides <bold>10b, k&#8211;m</bold>
<xref rid="sch2-fn1" ref-type="fn"/>
</title></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c01421_0011.jpg"/><p>
<fn id="sch2-fn1"><label>a</label><p>Reagents and conditions:
(i)
30% H<sub>2</sub>O<sub>2</sub>, AcOH, r. t.; (ii) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, 70 &#176;C.</p></fn>
</p></fig></sec><sec id="sec2.2"><title>Compound Binding to CA Isozymes</title><p>All synthesized compounds
were divided into 7 groups: <bold>4&#173;(a&#8211;d, f&#8211;m)</bold>, <bold>5&#173;(a&#8211;d, f, g, j&#8211;m)</bold>, <bold>6&#173;(b, c, e)</bold>, <bold>7&#173;(a, b, h, i, k&#8211;m)</bold>, <bold>8&#173;(a, k&#8211;m)</bold>, <bold>9&#173;(a&#8211;d, h, i, l, m)</bold>, and <bold>10&#173;(b, k&#8211;m)</bold> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>). Compounds
that started with numbers <bold>4</bold>, <bold>7</bold>, and <bold>9</bold> were 4-sulfanyl-, 4-sulfinyl, and 4-sulfonyl- substituted
esters, respectively. Compounds starting with the numbers <bold>5</bold>, <bold>8</bold>, and <bold>10</bold> were 4-sulfanyl-, 4-sulfinyl,
and 4-sulfonyl- substituted benzamides analogous to the previous series.
Compounds starting with the number <bold>6</bold> were 4-amino-substituted
benzamides. Various linear, branched, and cyclic aliphatic and aromatic
substituents at the <italic toggle="yes">ortho</italic> position were tested to
assess whether size, flexibility, and hydrophobicity affect affinity.
Compound affinities for the 12 catalytically active human CA isozymes
are listed in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Chemical structures of the compounds synthesized and investigated
in this study. Compounds <bold>1</bold>, <bold>2</bold>, and <bold>3</bold> are the starting compounds of the synthesis shown in <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c01421_0001.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>
<italic toggle="yes">Observed</italic> and <italic toggle="yes">Intrinsic</italic> (<italic toggle="yes">K</italic>
<sub>d,obs</sub> and <italic toggle="yes">K</italic>
<sub>d,int</sub>) Dissociation Constants (in nM Units)
of Investigated Compounds to All Catalytically Active Human CAs at
37 &#176;C Obtained by Fluorescent Thermal Shift Assay (FTSA)<xref rid="t1fn1" ref-type="table-fn"/>
</title></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c01421_0012.jpg"/><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c01421_0013.jpg"/><graphic id="GRAPHIC-d14e614-autogenerated" position="float" orientation="portrait" xlink:href="jm5c01421_0017.jpg"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Observed values were determined
using 50 mM sodium phosphate buffer at pH 7.0 containing 100 mM sodium
chloride, 50 &#956;M ANS dye, and 2% (v/v) DMSO. <italic toggle="yes">K</italic>
<sub>d,int</sub>s were calculated according to <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula"/>
</xref> (see the <xref rid="sec5" ref-type="sec">Experimental Section</xref>). Values with a &#8220;&#8805;&#8221; sign show that they are
at the detection limit of &#8805;200 000 nM of <italic toggle="yes">K</italic>
<sub>d,obs</sub> according to the highest used ligand concentration.
The intrinsic value limits vary for different CAs and compounds due
to differences in p<italic toggle="yes">K</italic>
<sub>a</sub>. p<italic toggle="yes">K</italic>
<sub>a,SA</sub> &#8211; p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide
group; p<italic toggle="yes">K</italic>
<sub>a,CA</sub> &#8211; p<italic toggle="yes">K</italic>
<sub>a</sub> value of water molecule bound to Zn&#173;(II) in the active
site of CA; AZM, acetazolamide (a standard inhibitor).</p></fn><fn id="t1fn2"><label>b</label><p>Not determined due to solubility
issues or low intensity of the spectrum curves. The p<italic toggle="yes">K</italic>
<sub>a,SA</sub> value was assigned based on similarities in chemical
structure.</p></fn></table-wrap-foot></table-wrap><p>As one of the important findings in
this manuscript, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref> arranges the compounds in
the order of their affinity for CAIX and compared to undesired target
CAII. A high affinity for CAIX is desired, because CAIX is implicated
in various types of cancer.<xref rid="ref24" ref-type="bibr"/> However,
CAII is abundant in erythrocytes, thus an off-target for anticancer
inhibitors.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Compounds are arranged in the order of increasing affinity for
CAIX. Compound <bold>4b</bold> had the highest affinity and selectivity
for CAIX. The intrinsic dissociation constants (in nM units) are compared
for CAII and CAIX, while values for the remaining CAs are listed in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c01421_0002.jpg"/></fig><p>Compound affinities for human CA isozymes were
analyzed using fluorescence-based
thermal shift assay (FTSA) and the enzymatic activity stopped-flow-based
inhibition assay (SFA) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). The FTSA determined the observed dissociation constants
for all compounds with all 12 CA isozymes (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and Supplementary <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>). From these experimentally determined <italic toggle="yes">K</italic>
<sub>d,obs</sub>, the <italic toggle="yes">intrinsic</italic> dissociation constants <italic toggle="yes">K</italic>
<sub>d,int</sub> were calculated, and the results are primarily
focused on them. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B,C shows two compounds with strong and weak affinity for CAII and
CAIX by FTSA. A single oxygen atom strongly diminished affinity for
both isozymes. The stopped-flow assay of CO<sub>2</sub> hydration
enzymatic activity inhibition confirmed that the compounds inhibited
CAIX and CAII (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D,E). Inhibition <italic toggle="yes">K</italic>
<sub>i</sub> values are presented
in <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>. The FTSA is a convenient technique
covering a significantly wider <italic toggle="yes">K</italic>
<sub>d</sub> range
than the SFA.<xref rid="ref25" ref-type="bibr"/>
</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Compound affinity was
determined by two assays in this study. (A)
Chemical structures of two compounds whose binding data are shown
below. (B) and (C) Fluorescent thermal shift assay data (FTSA) of
compounds <bold>4b</bold> (closed squares) and <bold>7b</bold> (open
circles) binding to CAII and CAIX, respectively. (D) and (E) Stopped-flow
carbon dioxide hydration assay (SFA) data of compounds <bold>4b</bold> (closed squares) and <bold>7b</bold> (open circles) inhibition of
CAII and CAIX, respectively. The dissociation constants (<italic toggle="yes">K</italic>
<sub>d</sub>) or inhibition constants (<italic toggle="yes">K</italic>
<sub>i</sub>) are given next to the corresponding curves. It is important to
note that the experimental conditions of the methods were slightly
different: FTSA, pH 7.0, 37 &#176;C, while for SFA, pH 7.5, 25 &#176;C.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c01421_0003.jpg"/></fig><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Inhibition Constants and IC<sub>50</sub> (in nM Units) of CAII and CAIX with Compounds Obtained by Stopped-Flow
Carbon Dioxide Hydration Assay (SFA) at 25 &#176;C<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" char="&#xB1;" rowspan="1">
<italic toggle="yes">K</italic>
<sub>i</sub> (nM)<hr/></th><th colspan="2" align="center" char="&#xB1;" rowspan="1">
<italic toggle="yes">IC</italic>
<sub>50</sub> (nM)<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">compound</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">CAII</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">CAIX</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">CAII</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">CAIX</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>4a</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">25
&#177; 1.3</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">5.4 &#177; 0.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">47 &#177; 2.6</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">12 &#177; 0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4b</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">270 &#177; 20</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.6 &#177; 0.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">530
&#177; 40</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">16 &#177; 1.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4c</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">210 &#177; 30</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">37 &#177; 3.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">400 &#177; 50</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">79 &#177; 7</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4d</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">120 &#177; 10</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">51 &#177;
6</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">230 &#177; 20</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">110 &#177; 12</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4h</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9200 &#177; 500</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1300 &#177; 200</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">18,000 &#177; 1000</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2700
&#177; 400</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7a</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">63 &#177; 6</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">360 &#177; 30</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">120 &#177;
12</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">760 &#177; 60</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7b</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">64,000&#160;&#177;&#160;7500</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">86,000&#160;&#177;&#160;16,000</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">100,000&#160;&#177;&#160;10,000</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">200,000&#160;&#177;&#160;30,000</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7h</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">3400 &#177; 200</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7600 &#177; 700</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">6500 &#177; 300</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">16,000 &#177; 1600</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>9a</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">34,000 &#177; 4000</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">3700 &#177; 600</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">65,000 &#177; 7000</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7800 &#177; 1300</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Experiments were performed using
20 mM HEPES Na at pH 7.5, 20 mM Na<sub>2</sub>SO<sub>4</sub>, and
0.2 mM Phenol Red.</p></fn></table-wrap-foot></table-wrap><p>The experimental conditions slightly differed between
FTSA and
SFA, and it is therefore not appropriate to directly compare the <italic toggle="yes">K</italic>
<sub>d,obs</sub> and <italic toggle="yes">K</italic>
<sub>i</sub>. However,
the measured affinities were similar in both techniques. Further analysis
is based on FTSA data due to its wider limits in identifying strong
binders. Note that the enzyme concentration limits the SFA&#8217;s
ability to determine high-affinity binders. For example, if we use
a 10 nM concentration of a CA isozyme, the lowest IC<sub>50</sub> is
5 nM, half of the protein concentration. Any compound with an <italic toggle="yes">IC</italic>
<sub>50</sub> stronger than 5 nM would exhibit a dosing
curve that appears as an <italic toggle="yes">IC</italic>
<sub>50</sub> of 5 nM.
Thus, compounds that possess single-digit nM or picomolar <italic toggle="yes">K</italic>
<sub>d</sub>, cannot be distinguished by SFA.</p><p>Sulfonamide
binding of CA is a pH-dependent reaction.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content> The water molecule bound to the
CA zinc ion is replaced by the deprotonated form of sulfonamide upon
binding.<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>,<xref rid="ref29" ref-type="bibr"/>
</named-content> The protonation forms required for the interaction
exist at different pHs: the CA-Zn&#173;(II)-H<sub>2</sub>O has the largest
fraction at acidic pH and the deprotonated sulfonamide has the largest
fraction at alkaline pH. Therefore, the measured affinity is always
lower than the intrinsic affinity. The intrinsic parameters are calculated
(see equations in the Experimental section) by knowing the p<italic toggle="yes">K</italic>
<sub>a</sub> of the CA zinc-bound water and the p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide group (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>). Experimental data of the sulfonamide group p<italic toggle="yes">K</italic>
<sub>a</sub> determination for compound <bold>4b</bold> are shown
in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>. <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S3</ext-link> shows the graphs of p<italic toggle="yes">K</italic>
<sub>a</sub> determination for the remaining compounds.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Spectrophotometric
determination of the sulfonamide group deprotonation
p<italic toggle="yes">K</italic>
<sub>a</sub> for compound <bold>4b</bold>. (A)
Absorption spectra of compound <bold>4b</bold> in solutions at various
pH at intervals of 0.5 pH units at 37 &#176;C. (B) Normalized absorbance
at 260 nm was plotted as a function of pH, and the p<italic toggle="yes">K</italic>
<sub>a</sub> value was determined as a midpoint of the curve. The
data points are the mean points of two repeats ((A) shows one repeat
for simplicity), with standard deviations. The p<italic toggle="yes">K</italic>
<sub>a</sub> value of compound <bold>4b</bold> was 9.74 &#177; 0.13
(&#177;1.3%) with a confidence interval [9.62&#8211;9.87] of 95%.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c01421_0004.jpg"/></fig><p>Intrinsic affinities are especially important in
rational drug
design. It is not rare when a stronger affinity is observed not because
of the formed bonds but because of the substitutions that lower the
p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide group and thus
increase the fraction of the ready-to-bind form.<xref rid="ref30" ref-type="bibr"/> Intrinsic parameters are used to avoid misleading conclusions
when comparing the affinity of compounds for CAs.</p><sec id="sec2.2.1"><title>Esters vs Benzamides</title><p>4-sulfanyl-substituted esters <bold>4a</bold>&#8211;<bold>d</bold>, <bold>f&#8211;m</bold> were the
largest (12 compounds) studied group of compounds with the same framework.
Compounds of this group, even almost independently of the substituent,
interacted strongly and selectively with several CAs. <italic toggle="yes">K</italic>
<sub>d,int</sub> of <bold>4b</bold> for CAIX was 0.0010 nM and it
was the strongest interaction measured in this study, CAXIII&#58872;0.090
nM and CAXIV&#58872;0.020 nM, with others interacting much weaker.
The size of the substituent was critical in this interaction. CAIX
has a larger active site than the rest of the CAs.<xref rid="ref31" ref-type="bibr"/> It was interesting that compound <bold>4g</bold> (<italic toggle="yes">adamantyl</italic>), which has a similar affinity for CAIX (<italic toggle="yes">K</italic>
<sub>d,int</sub> = 0.0030 nM) to most of the compounds
in this group, is a few hundred times more selective for CAIX, whereas,
for example, <bold>4b</bold> (<italic toggle="yes">cyclohexyl</italic>) is only
a few tens of times more selective for CAIX and can be considered
a strong binder to several undesired CAs. On the other hand, the 4-methylsulfanyl-
substituted compound <bold>4h</bold> is no longer selective. Thus,
the hydrophobic interaction made a significant contribution to affinity
for CAIX, and selectivity was mainly obtained by the size of the substituent
when the binding to CAIX was optimal and binding to other CAs was
limited by steric interference. Analogous benzamides were much weaker
binders of CAs. Most benzamides exhibited no interaction with CAs.
Nevertheless, all compounds in this series bound to CAIX and were,
in most cases, at least several dozen times more selective for it
than for other CAs.</p></sec><sec id="sec2.2.2"><title>Sulfanyl vs Sulfinyl vs Sulfonyl Compounds</title><p>Different
forms of sulfur oxidation led to drastically different affinities
for CAs. A higher degree of oxidation in these compounds weakened
the affinity. However, in our opinion, it was not the oxidation itself
that had the main influence, but rather the conformation of the compound.
The affinity of all sulfinyl- compounds with all CAs was significantly
weaker than analogous sulfanyl- compounds. The decrease in affinity
varied depending on the CA isozyme and the substituents. Therefore,
no generalized observations could be made. For example, compound <bold>7a</bold> did not bind to CAI and CAVA, but the weak affinity was
determined for CAIII, with all other CAs the interactions were similar
and did not exceed more than 10-fold in most cases and there was no
selectivity for CAIX. Compounds <bold>7b</bold>, <bold>7h</bold>,
and <bold>7i</bold> did not bind or bind weakly and nonselectively
to all CAs. Except for <bold>7b</bold>, it is bound only to CAIX with
28 nM. The <italic toggle="yes">K</italic>
<sub>d,int</sub> of compounds <bold>7k</bold>, <bold>7l</bold>, and <bold>7m</bold> were 0.63, 0.72, and 0.24
nM, respectively. Also, there was a similar affinity for CAXIII and
CAXIV and weaker for the other CAs. From compounds <bold>5&#173;(a&#8211;d,
f, g, j&#8211;m)</bold> to <bold>8&#173;(a, k&#8211;m)</bold> decreased
affinity for all CAs.</p><p>Switching to sulfonyl compounds reduced
the affinity and abolished the selectivity for CAIX. <bold>9b</bold> only bound to CAVII, CAIX, CAXIII, and CAXIV with <italic toggle="yes">K</italic>
<sub>d,int</sub> 130, 320, 1100, and 680 nM, respectively. The most
strongly interacting compound in this series was <bold>9i</bold>,
e.g., <italic toggle="yes">K</italic>
<sub>d,int</sub> of CAVI&#58872;1.7 nM, CAIX&#58872;3.2
nM but also bound to other CAs quite similarly. Meanwhile, compounds <bold>10&#173;(b, k&#8211;m)</bold> did not bind to any isozymes, only a couple
of measurements showed a weak interaction.</p></sec><sec id="sec2.2.3"><title>4-Sulfanyl- vs 4-Amino-Substituted</title><p>Comparing <bold>5b</bold> vs. <bold>6b</bold> and <bold>5c</bold> vs. <bold>6c</bold>, in most cases, the dissociation constants differed only a few times,
and the constants for CAIX did not exceed the margin of error. The
S or N atom in the same position of the compound almost did not change
the affinity for all isozymes. Compound <bold>6e</bold> (cyclooctyl-substituted)
selectively interacted with CAIX, <italic toggle="yes">K</italic>
<sub>d,int</sub> of CAIX&#58872;0.53 nM, CAXII&#58872;39 nM, and CAXIV&#58872;12
nM. It did not bind to other CAs. Most likely the selectivity was
due to the size of the active site pocket.</p></sec></sec><sec id="sec2.3"><title>X-ray Crystal Structures of Compound Binding to CAII and CAXIII</title><p>Nine crystal structures were determined by X-ray crystallography,
the complexes of CAII with compounds <bold>2</bold>, <bold>3</bold>, <bold>4c</bold>, <bold>4d, 4h</bold>, CAIX with <bold>4d</bold> and <bold>5b</bold>, and CAXIII with <bold>4c</bold> and <bold>4d</bold>. <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref> lists the
data collection and refinement statistics. <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> shows the electron density maps of these
compounds in the active site of CAs. Two molecules of compound <bold>4h</bold> were identified in the active site of CAII, one conventionally
formed a coordination bond between the sulfonamide group and zinc,
and the other was independently located near the periphery of the
active site. The localization of both separated molecules relative
to the same zinc is shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>E,F. The main highlights of the identified protein&#8211;ligand
interactions are described below and illustrated in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>.</p><table-wrap position="float" id="tbl3" orientation="landscape"><label>3</label><caption><title>X-ray Diffraction Data Collection
and Refinement Statistics</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">isozyme&#58872;ligand</th><th align="center" colspan="1" rowspan="1">CAII&#58872;<bold>2</bold>
</th><th align="center" colspan="1" rowspan="1">CAII&#58872;<bold>3</bold>
</th><th align="center" colspan="1" rowspan="1">CAII&#58872;<bold>4c</bold>
</th><th align="center" colspan="1" rowspan="1">CAII&#58872;<bold>4d</bold>
</th><th align="center" colspan="1" rowspan="1">CAII&#58872;<bold>4h</bold>
</th><th align="center" colspan="1" rowspan="1">CAIX&#58872;<bold>4d</bold>
</th><th align="center" colspan="1" rowspan="1">CAIX&#58872;<bold>5b</bold>
</th><th align="center" colspan="1" rowspan="1">CAXIII&#8211;<bold>4c</bold>
</th><th align="center" colspan="1" rowspan="1">CAXIII&#8211;<bold>4d</bold>
</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1">PDB ID</td><td align="left" colspan="1" rowspan="1">9FPT</td><td align="left" colspan="1" rowspan="1">9FPU</td><td align="left" colspan="1" rowspan="1">9FPQ</td><td align="left" colspan="1" rowspan="1">9FPR</td><td align="left" colspan="1" rowspan="1">9FPS</td><td align="left" colspan="1" rowspan="1">9R8X</td><td align="left" colspan="1" rowspan="1">9R8Y</td><td align="left" colspan="1" rowspan="1">9FPV</td><td align="left" colspan="1" rowspan="1">9FPW</td></tr><tr><td colspan="10" align="center" rowspan="1">Data Collection Statistics</td></tr><tr><td align="center" colspan="1" rowspan="1">space group</td><td align="left" colspan="1" rowspan="1">P12<sub>1</sub>1</td><td align="left" colspan="1" rowspan="1">P12<sub>1</sub>1</td><td align="left" colspan="1" rowspan="1">P12<sub>1</sub>1</td><td align="left" colspan="1" rowspan="1">P12<sub>1</sub>1</td><td align="left" colspan="1" rowspan="1">P12<sub>1</sub>1</td><td align="left" colspan="1" rowspan="1">H3</td><td align="left" colspan="1" rowspan="1">H3</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td></tr><tr><td align="center" colspan="1" rowspan="1">unit-cell parameters (<italic toggle="yes">a</italic>, <italic toggle="yes">b</italic>, <italic toggle="yes">c</italic> (&#197;); &#945;, &#946;, &#947; (&#176;))</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 42.1, <italic toggle="yes">b</italic> = 40.9, <italic toggle="yes">c</italic> = 71.7, &#945; = &#947; = 90, &#946; = 104.0</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 42.0, <italic toggle="yes">b</italic> = 41.1, <italic toggle="yes">c</italic> = 71.9, &#945; = &#947; = 90, &#946; = 104.2</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 42.3, <italic toggle="yes">b</italic> = 41.3, <italic toggle="yes">c</italic> = 72.2, &#945; = &#947; = 90, &#946; = 104.2</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 42.3, <italic toggle="yes">b</italic> = 41.3, <italic toggle="yes">c</italic> = 72.1, &#945; = &#947; = 90, &#946; = 104.5</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 42.3, <italic toggle="yes">b</italic> = 41.2, <italic toggle="yes">c</italic> = 72.0, &#945; = &#947; = 90, &#946; = 104.4</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = <italic toggle="yes">b</italic> = 152.5, <italic toggle="yes">c</italic> = 172.4, &#945; = &#946; = 90, &#947; = 120</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = <italic toggle="yes">b</italic> = 151.9, <italic toggle="yes">c</italic> = 173.7,
&#945; = &#946; = 90, &#947; = 120</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 55.1, <italic toggle="yes">b</italic> = 58.0, <italic toggle="yes">c</italic> = 160.2, &#945;
= &#946; = &#947; = 90</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">a</italic> = 55.5, <italic toggle="yes">b</italic> = 58.4, <italic toggle="yes">c</italic> = 160.7, &#945; = &#946;
= &#947; = 90</td></tr><tr><td align="center" colspan="1" rowspan="1">resolution range (&#197;)</td><td align="left" colspan="1" rowspan="1">69.6&#8211;1.2</td><td align="left" colspan="1" rowspan="1">40.7&#8211;1.1</td><td align="left" colspan="1" rowspan="1">70.0&#8211;1.5</td><td align="left" colspan="1" rowspan="1">40.0&#8211;1.5</td><td align="left" colspan="1" rowspan="1">39.9&#8211;1.4</td><td align="left" colspan="1" rowspan="1">47.95&#8211;2.0</td><td align="left" colspan="1" rowspan="1">47.8&#8211;1.95</td><td align="left" colspan="1" rowspan="1">80.1&#8211;1.7</td><td align="left" colspan="1" rowspan="1">40.2&#8211;1.9</td></tr><tr><td align="center" colspan="1" rowspan="1">unique reflections number</td><td align="left" colspan="1" rowspan="1">75321</td><td align="left" colspan="1" rowspan="1">87594</td><td align="left" colspan="1" rowspan="1">38824</td><td align="left" colspan="1" rowspan="1">41447</td><td align="left" colspan="1" rowspan="1">47284</td><td align="left" colspan="1" rowspan="1">101012</td><td align="left" colspan="1" rowspan="1">108927</td><td align="left" colspan="1" rowspan="1">57402</td><td align="left" colspan="1" rowspan="1">42102</td></tr><tr><td align="center" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sub>merge</sub>, overall (outer
shell)</td><td align="left" colspan="1" rowspan="1">0.04 (0.38)</td><td align="left" colspan="1" rowspan="1">0.05 (0.31)</td><td align="left" colspan="1" rowspan="1">0.05 (0.25)</td><td align="left" colspan="1" rowspan="1">0.05 (0.39)</td><td align="left" colspan="1" rowspan="1">0.04 (0.38)</td><td align="left" colspan="1" rowspan="1">0.08 (1.18)</td><td align="left" colspan="1" rowspan="1">0.21 (1.30)</td><td align="left" colspan="1" rowspan="1">0.09&#160;(0.32)</td><td align="left" colspan="1" rowspan="1">0.12&#160;(0.31)</td></tr><tr><td align="center" colspan="1" rowspan="1">I/&#963; overall (outer shell)</td><td align="left" colspan="1" rowspan="1">16.9 (3.5)</td><td align="left" colspan="1" rowspan="1">13.7 (3.8)</td><td align="left" colspan="1" rowspan="1">15.9 (4.9)</td><td align="left" colspan="1" rowspan="1">19.6 (4.6)</td><td align="left" colspan="1" rowspan="1">24.2 (4.7)</td><td align="left" colspan="1" rowspan="1">21.1 (2.3)</td><td align="left" colspan="1" rowspan="1">7.1 (1.5)</td><td align="left" colspan="1" rowspan="1">16.8 (7.4)</td><td align="left" colspan="1" rowspan="1">13.0 (7.6)</td></tr><tr><td align="center" colspan="1" rowspan="1">multiplicity overall (outer shell)</td><td align="left" colspan="1" rowspan="1">6.8 (6.7)</td><td align="left" colspan="1" rowspan="1">6.6 (6.0)</td><td align="left" colspan="1" rowspan="1">6.6 (6.4)</td><td align="left" colspan="1" rowspan="1">7.0 (6.9)</td><td align="left" colspan="1" rowspan="1">7.0 (6.8)</td><td align="left" colspan="1" rowspan="1">10.4 (10.5)</td><td align="left" colspan="1" rowspan="1">10.4 (9.9)</td><td align="left" colspan="1" rowspan="1">13.2 (13.1)</td><td align="left" colspan="1" rowspan="1">13.1 (13.4)</td></tr><tr><td align="center" colspan="1" rowspan="1">completeness (%) overall (outer shell)</td><td align="left" colspan="1" rowspan="1">96.7&#160;(94.0)</td><td align="left" colspan="1" rowspan="1">96.0&#160;(91.3)</td><td align="left" colspan="1" rowspan="1">99.6&#160;(99.2)</td><td align="left" colspan="1" rowspan="1">98.7&#160;(97.7)</td><td align="left" colspan="1" rowspan="1">97.6&#160;(94.9)</td><td align="left" colspan="1" rowspan="1">100.0&#160;(100.0)</td><td align="left" colspan="1" rowspan="1">100.0&#160;(100.0)</td><td align="left" colspan="1" rowspan="1">100 (100)</td><td align="left" colspan="1" rowspan="1">100
(100)</td></tr><tr><td align="center" colspan="1" rowspan="1">Wilson B-factor</td><td align="left" colspan="1" rowspan="1">12.8</td><td align="left" colspan="1" rowspan="1">11.4</td><td align="left" colspan="1" rowspan="1">17.8</td><td align="left" colspan="1" rowspan="1">15.5</td><td align="left" colspan="1" rowspan="1">17.0</td><td align="left" colspan="1" rowspan="1">28.0</td><td align="left" colspan="1" rowspan="1">22.4</td><td align="left" colspan="1" rowspan="1">16.9</td><td align="left" colspan="1" rowspan="1">22.5</td></tr><tr><td colspan="10" align="center" rowspan="1">Refinement Statistics</td></tr><tr><td align="center" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sub>work</sub>
</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1">0.19</td></tr><tr><td align="center" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sub>free</sub>
</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">0.20</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">0.19</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">0.19</td><td align="left" colspan="1" rowspan="1">0.23</td></tr><tr><td align="center" colspan="1" rowspan="1">RMSD bond lengths (&#197;)/ angles (&#176;)</td><td align="left" colspan="1" rowspan="1">0.02/2.13</td><td align="left" colspan="1" rowspan="1">0.02/2.26</td><td align="left" colspan="1" rowspan="1">0.01/1.80</td><td align="left" colspan="1" rowspan="1">0.01/2.04</td><td align="left" colspan="1" rowspan="1">0.01/2.02</td><td align="left" colspan="1" rowspan="1">0.01/1.81</td><td align="left" colspan="1" rowspan="1">0.01/1.73</td><td align="left" colspan="1" rowspan="1">0.01/1.90</td><td align="left" colspan="1" rowspan="1">0.01/1.57</td></tr><tr><td align="center" colspan="1" rowspan="1">average B factors (&#197;<sup>2</sup>): all atoms/inhibitors</td><td align="left" colspan="1" rowspan="1">22.7/17.2</td><td align="left" colspan="1" rowspan="1">19.6/16.9</td><td align="left" colspan="1" rowspan="1">21.6/21.9</td><td align="left" colspan="1" rowspan="1">20.1/15.7</td><td align="left" colspan="1" rowspan="1">21.8/21.7</td><td align="left" colspan="1" rowspan="1">31.9/50.4</td><td align="left" colspan="1" rowspan="1">30.7/39.4</td><td align="left" colspan="1" rowspan="1">21.6/32.5</td><td align="left" colspan="1" rowspan="1">25.9/35.6</td></tr><tr><td align="center" colspan="1" rowspan="1">Ramachandran statistics (%): favored/allowed/outliers</td><td align="left" colspan="1" rowspan="1">97/3/ 0</td><td align="left" colspan="1" rowspan="1">97/3/ 0</td><td align="left" colspan="1" rowspan="1">97/3/ 0</td><td align="left" colspan="1" rowspan="1">96/4/ 0</td><td align="left" colspan="1" rowspan="1">96/4/ 0</td><td align="left" colspan="1" rowspan="1">96/4/ 0.11</td><td align="left" colspan="1" rowspan="1">94/5/ 0.32</td><td align="left" colspan="1" rowspan="1">chain A: 98/2/ 0 chain B: 97/3/ 0</td><td align="left" colspan="1" rowspan="1">chain A: 97/3/ 0 chain B: 97/3/ 0</td></tr></tbody></table></table-wrap><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>|<italic toggle="yes">F</italic>(<italic toggle="yes">o</italic>) &#8211; <italic toggle="yes">F</italic>(<italic toggle="yes">c</italic>)| omit maps at 3&#963; in green for the investigated
ligands in the active site of CAs. (A) CAII&#58872;<bold>2</bold> (PDB
ID: 9FPT), (B) CAII&#58872;<bold>3</bold> (PDB ID: 9FPU), (C) CAII&#58872;<bold>4c</bold> (PDB ID: 9FPQ), (D) CAII&#58872;<bold>4d</bold> (PDB ID:
9FPR), (E) and (F) CAII&#58872;<bold>4h</bold> (PDB ID: 9FPS; two
ligand molecules were identified, one bound directly to Zn in a conventional
position, while the second was seen located nearby toward the edge
of the active site), (G) CAIX&#58872;<bold>5b</bold> (PDB ID: 9R8Y),
(H) CAIX&#58872;<bold>4d</bold> (PDB ID: 9R8X), <bold>(J)</bold> CAXIII&#58872;<bold>4c</bold> (PDB ID: 9FPV), <bold>(K)</bold> CAXIII&#58872;<bold>4d</bold> (PDB ID: 9FPW). Omit maps were taken from a refinement run of the
final model without the ligand. Zinc is shown in blue.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c01421_0005.jpg"/></fig><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>X-ray crystal structures of (A) CAII&#58872;<bold>2</bold> (PDB
ID: 9FPT), (B) CAII&#58872;<bold>3</bold> (PDB ID: 9FPU), (C) CAII&#58872;<bold>4c</bold> (PDB ID: 9FPQ), (D) CAII&#58872;<bold>4d</bold> (PDB ID:
9FPR), (E) and (F) CAII&#58872;<bold>4h</bold> (PDB ID: 9FPS; two
ligand molecules were identified, one bound directly (E) to Zn in
a conventional position, while the second is seen located nearby toward
the edge (F) of the active site), (G) CAIX&#58872;<bold>5b</bold> (PDB
ID: 9R8Y), (H) CAIX&#58872;<bold>4d</bold> (PDB ID: 9R8X), <bold>(J)</bold> CAXIII&#58872;<bold>4c</bold> (PDB ID: 9FPV), <bold>(K)</bold> CAXIII&#58872;<bold>4d</bold> (PDB ID: 9FPW). The yellow dashed line represents the hydrogen
bond; the distances are given in angstroms. The amino acids directly
involved in hydrogen bond formation are labeled. Amino acids are colored
according to hydrophobicity:<xref rid="ref32" ref-type="bibr"/> the most
intense red color represents the most hydrophobic amino acids.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c01421_0006.jpg"/></fig><sec id="sec2.3.1"><title>Structures of <bold>2</bold> vs <bold>3</bold> Bound to CAII</title><p>Starting compounds <bold>2</bold> and <bold>3</bold> used in the
synthesis differed by one substitution at the <italic toggle="yes">meta</italic> position relative to the sulfonamide group, ester vs. amide. <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A,B shows the position
of these compounds in the active site of CAII. Both compounds retained
the same position of the sulfonamide group and the chlorine atom in
the active site of CAII. The amide substituent formed multiple hydrogen
bonds with the amino acid side groups, while the ester was stabilized
by a network of hydrogen bonds through water molecules. Presumably,
a different network of hydrogen bonds pulled the entire molecule slightly,
so a partially rotated benzene ring was observed in the crystal structure.
No significant conformational changes were observed in the amino acid
chains of the active site of CAII. However, the amide substituent
of the compound was not in one fixed position. Instead, 3 alternative
conformations of the substituent were identified in the structure.
However, it should be noted that this substituent has a poor electron
density, likely due to its high flexibility. Consequently, its exact
arrangement cannot be determined.</p></sec><sec id="sec2.3.2"><title>Structures of CAII with Chlorine-Substituted (<bold>2</bold>, <bold>3</bold>) vs Sulfanyl-Substituted (<bold>4c</bold>, <bold>4d</bold>, and <bold>4h</bold>)</title><p>The position of <italic toggle="yes">ortho-sulfanyl</italic> and chlorine-substituted compounds in the
CAII active site differed significantly. The entire sulfanyl-substituted
molecule was shifted to avoid steric interference but maintained a
similar distance between the sulfonamide group&#8217;s nitrogen and
the enzyme&#8217;s zinc compared to the chlorine-substituted compound.
Meanwhile, the studied <italic toggle="yes">ortho</italic>-substituted compounds
occupied similar positions, and the ester groups of all three compounds
formed a hydrogen bond with Asn62. Notably, the electron density of
all inhibitor molecules is well-defined.</p></sec><sec id="sec2.3.3"><title>Structures of CAII vs CAIX and CAXIII with Bound Sulfanyl-Substituted
(<bold>4c</bold> and <bold>4d</bold> or <bold>5b</bold>)</title><p>
<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> shows the
interactions between CAII with compounds <bold>4c</bold> and <bold>4d</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>C,D), CAIX with <bold>4d</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>H), and CAXIII with compounds <bold>4c</bold> and <bold>4d</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>J,K). One of the main differences was in the formed hydrogen
bonds. The oxygen of the ester group of the compound formed a direct
hydrogen bond with Asn62 in the active site of CAII. Meanwhile, a
hydrogen bond is formed in the active site of CAIX and CAXIII through
a water molecule with Gln70 and Asn65 or Ser64 and Asn69, respectively.
Asn62 in CAII, Asn65 in CAIX, and Asn69 in CAXIII differ only by the
numbering but correspond to the same position.</p><p>Incidentally,
compound <bold>5b</bold> CAIX also forms the same hydrogen bond through
a water molecule, and the entire molecule adopts a similar conformation.
Notably, the electron density of the 17 amino acids at the N-terminus
of both X-ray crystal structures of CAIX is not defined as expected.
These amino acids fold in their 3D structure to form the active site
of the protein. This side of the active site is called the hydrophilic
part. This suggests that the bound ligand pushes these amino acids
to fit fully into the active site. When comparing these structures
(PDB ID: 9R8X and 9R8Y) with those existing in the PDB (e.g., PDB
ID: <ext-link xlink:href="3iai" ext-link-type="PDB">3iai</ext-link>), the
clash between ligand and Tyr7 is seen without changing their arrangement.</p><p>It is important to emphasize that both <bold>4c</bold> and <bold>4d</bold> have very poor electron density in the CAXIII active center,
so the arrangement of the compound should be evaluated more cautiously.
On the other hand, a comparison of the structures shows that compound <bold>4d</bold> is more similarly located in the active sites of CAII and
CAXIII, while in CAIX, it is shifted toward the hydrophilic side,
which, as mentioned, is not fully visible in the X-ray structure.</p></sec><sec id="sec2.3.4"><title>Atypical Binding Position</title><p>The structure 9FPS was unique
because two ligand molecules were identified as bound in the active
site. One molecule was bound classically and formed a coordination
bond with the zinc ion. The second formed a hydrophobic interaction
with the first molecule, and hydrogen bonds with water molecules located
toward the edge of the active site. This could be a crystallographic
artifact or a secondary interaction with the protein.<xref rid="ref33" ref-type="bibr"/> A previous publication<xref rid="ref2" ref-type="bibr"/> identified
a similar case with CAIX (PDB ID: <ext-link xlink:href="6QUT" ext-link-type="PDB">6QUT</ext-link>) (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). In that case, the molecules interacted in the active
site and among themselves between the chains in an asymmetric unit.
This case with CAII was different because the two chains had no interaction
between ligand molecules. The active sites of symmetric chains were
not oriented face-to-face. The atoms of the second nonclassical ligand
were further than 5&#197; from the amino acids of the symmetric chain.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Unusual
ligand positions in crystal structures of CAII (PDB ID:
9FPS) and CAIX (PDB ID: <ext-link xlink:href="6QUT" ext-link-type="PDB">6QUT</ext-link>, published previously<xref rid="ref2" ref-type="bibr"/>).
The chemical structures of the ligands are shown above the crystal
structures. The crystal structures represent a view of the monomers
and a zoomed-in view of the active site. Zn&#173;(II) is shown as a pink
sphere. Bound to Zn&#173;(II) inhibitor molecules are green and others are
blue. (A) Monomer of CAII is shown in surface mode and colored salmon.
The symmetric chain is colored white. (B) In the case of CAIX, only
the asymmetric unit is represented. Six inhibitor molecules are bound
to 4 CA IX chains. Chain C (orange) and chain D (salmon) have two
inhibitor molecules, and chains A and B (beige) have one molecule.
In this case, the interaction of ligands between separate chains is
visible.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c01421_0007.jpg"/></fig></sec></sec><sec id="sec2.4"><title>Molecular Docking</title><p>To understand the differences in
the binding affinities of series <bold>4</bold>, <bold>7</bold>, and <bold>9</bold> ligands, they were docked into CAII, except for <bold>4e</bold> and <bold>4f</bold>, containing large, flexible rings that are challenging
to dock. Series <bold>4</bold> ligands were also docked into CAIX
and CAXIII, to compare with crystal structures and thus assess the
docking accuracy. To reduce bias, different receptors (PDB IDs &#8211;
CAII: 3HS4; CAIX: 6G9U, chain A; CAXIII: 4KNN, chain A) were chosen
instead of the new X-ray structures presented in this paper.</p><p>To mimic the donor&#8211;acceptor bond between the zinc ion and
the sulfonamide nitrogen of the ligand, we employed constrained docking
using the Smina program.<xref rid="ref34" ref-type="bibr"/> The constraint
forced the sulfonamide nitrogen to maintain its original position
in the X-ray structure. The generated poses were afterward rescored
using the Vinardo scoring function.<xref rid="ref35" ref-type="bibr"/> Vina<xref rid="ref36" ref-type="bibr"/> and GNINA<xref rid="ref37" ref-type="bibr"/> Machine-learning-based
scoring functions were found to be inferior to Vinardo for this system,
and therefore only the latter was employed for further analysis. The
pose with the best rescored affinity that matched the X-ray conformation
of the benzenesulfonamide moiety was then chosen as the representative
best docked structure (in all cases, for ligand <bold>4</bold> series,
it was ranked 1 by Vinardo, except for <bold>4j</bold>, where the
correct benzenesulfonamide conformation was ranked 3). The best docked
poses for CAII are shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>A. The Pearson correlation coefficient <italic toggle="yes">R</italic> with the experimental <italic toggle="yes">intrinsic</italic> binding affinities
to CAII for the best docked poses was 0.87. <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>B plots the corresponding computed and experimental
binding affinities for CAII and CAIX (values listed in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Table S1</ext-link> in the Supporting Information). Notably,
for CAII, the scoring function correctly predicts the best binder, <bold>4m</bold>, and the four worst binders (<bold>4g</bold>&#8211;<bold>j</bold>). The panel also shows the correspondence between the experimental
and predicted binding affinities for CAIX, with <italic toggle="yes">R</italic> = 0.66.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>(A) Docked series <bold>4</bold> ligands (see main text for details)
superposed onto the X-ray structure of <bold>4c</bold> (PDB ID: 9FPQ;
rendered using ball-and-stick representation) in a complex with CAII.
Note that hydrophobic substituents stack against the Phe131 side chain.
(B) Computed ligand binding affinities to CAII (circles) and CAIX
(squares) using Vinardo scoring function plotted against the experimental
binding affinities&#58872;intrinsic Gibbs energy changes. The Pearson
correlations R of the plotted points are 0.87 for CAII and 0.66 for
CAIX. The large difference between the computed and experimental binding
affinities is because the Vinardo scoring function does not take into
account the interaction with zinc. However, it can be assumed to be
approximately equal for all ligands.</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c01421_0008.jpg"/></fig><sec id="sec2.4.1"><title>Validation of the Docking Protocol via Comparison with the X-ray
Structures</title><p>The proposed docking and scoring protocol was
further validated by comparing the predicted docked poses of some
of the ligands with their conformations in the newly reported X-ray
structures. <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S4A&#8211;C</ext-link> shows the
ranked poses of ligands <bold>4c</bold>, <bold>4d</bold>, and <bold>4h</bold> compared against their X-ray conformations in the complex
with CAII. The heavy atom Root Mean Square Deviation (RMSD) between
the docked and X-ray conformation is 2.03, 3.13, and 0.46 &#197;,
respectively. For the first two ligands, however, the rank 2 conformations
are close to the X-ray conformation (<bold>4c</bold>: 0.61 &#197;; <bold>4d</bold>: 0.67 &#197;, see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S4A,B</ext-link>).</p><p>To further validate the chosen docking protocol, <bold>4d</bold> and <bold>5b</bold> were docked into CAIX (PDB ID: <ext-link xlink:href="6G9U" ext-link-type="PDB">6G9U</ext-link>, chain A). The best-scored
poses after reranking using Vinardo are shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>. The corresponding heavy atom RMSDs for <bold>4d</bold> and <bold>5b</bold> are 2.18 and 0.92 &#197;, respectively, and
despite the RMSD for <bold>4d</bold> being above 2 &#197;, the binding
mode is captured by the docking reasonably well, especially since
the receptor used for docking was originally bound to a ligand from
a chemically different series.</p><p>Compounds <bold>4c</bold> and <bold>4d</bold> were also docked
into the CAXIII receptor (PDB ID: <ext-link xlink:href="4KNN" ext-link-type="PDB">4KNN</ext-link>, chain A). Similarly to CAIX, the docking
protocol picked the docked pose with the approximately correct binding
mode (with RMSDs equal to 1.90 and 0.95 &#197;, respectively) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S6</ext-link>).</p></sec><sec id="sec2.4.2"><title>Docking of Series <bold>7</bold> and <bold>9</bold> Compounds</title><p>Since series <bold>4</bold> compounds using the docking protocol
described above can reproduce the scaffold rather well and generally
seem to stack the hydrophobic substituents reasonably, we applied
a similar procedure by docking series <bold>9</bold> ligands into
CAII as a model protein, in hopes that it will help to explain a difference
between the binding affinities of series <bold>4</bold> and <bold>9</bold>. Docking using the same protocol led to comparable binding
affinities between the two series (not shown). However, experiments
indicate that <bold>9</bold> binds worse by several orders of magnitude,
and rescored constrained pose affinities for this series exhibit practically
no correlation with the experiment (<italic toggle="yes">R</italic> &#8773; 0.12).
A careful examination of the docking results for series <bold>9</bold> revealed the source of the poor binding affinities and the poor
performance of the docking score. <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>A displays the best ranking pose of <bold>9a</bold>. While the phenyl substituent of <bold>9a</bold> stacks
well with Phe131 side chain, the two sulfonyl moieties exhibit an
apparent clash against each other.</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>Best ranking docked pose of <bold>9a</bold>, (S)-<bold>7a</bold>, (R)-<bold>7a</bold>, and <bold>4a</bold> in
the active site of
CAII as a model protein. (A) Best-ranking docked pose of <bold>9a</bold>. While the phenyl substituent stacks well with the Phe131 side chain,
the two SO<sub>2</sub> moieties presumably clash. (B) Two conformations
of 2-(methylsulfonyl)&#173;benzenesulfonamide: Top: conformation with two
benzene-to-S bond dihedrals constrained so that it is similar to the
docked conformation in (A); bottom: lowest energy conformation with
an intramolecular H-bond that is likely to be found in solution. The
energy difference between the two rotamers computed using density
functional theory is 53.8 kJ/mol. The fact that the used scoring function
does not take into account this difference explains why the calculated
affinities (not shown) do not match the experimental values. (C),
(E) Best-ranked docked conformations of <italic toggle="yes">(S)-</italic> and <italic toggle="yes">(R)-</italic>
<bold>7a</bold>, correspondingly. (D), (F) Top: the
conformations 2-(methylsulfinyl)&#173;benzenesulfonamide, matching the docked
geometries in (C) and (E). Bottom: The lowest energy conformer with
an intramolecular H-bond, presumably existing in solution. The docked <italic toggle="yes">(R)-</italic> enantiomer is much more stable due to the lack of clashes
present in the docked <italic toggle="yes">(S)-</italic> enantiomer. (G) Best-ranking
docked pose of <bold>4a</bold>. (H) Two conformations of 2-methylsulfanylbenzenesulfonamide:
Top: the optimized with constraints conformation matching the docked
conformation; bottom: The lowest energy conformer. Compared with the
sulfinyl- and sulfonyl-forms, the docked conformation for the sulfanyl
analog is the most stable, which is also reflected in the binding
affinities.</p></caption><graphic id="gr13" position="float" orientation="portrait" xlink:href="jm5c01421_0009.jpg"/></fig><p>To further explore this clash, we ran simulations
of a simple compound
2-(methylsulfonyl)&#173;benzenesulfonamide containing sulfonamide and methylsulfonyl
groups at the <italic toggle="yes">ortho</italic>-positions on a benzene ring.
The lowest energy conformer for this compound was generated using
CREST software<xref rid="ref38" ref-type="bibr"/> using semiempirical GFN2-xTB
wave function,<xref rid="ref39" ref-type="bibr"/> and afterward reoptimized
in the implicit solvent using the Density Functional Theory (DFT)
approach with the GAMESS-US program.<xref rid="ref40" ref-type="bibr"/> In
the lowest energy conformer, sulfonamide nitrogen forms a hydrogen
bond with the sulfonyl oxygen at the <italic toggle="yes">ortho</italic> position
(<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B, bottom).
The approximate conformational energy of the docked conformation was
also computed using DFT, keeping frozen the sulfonamide S&#8211;N
and methylsulfonyl S&#8211;C bond torsional angles for the benzene
ring, and optimizing the rest of the 2-methylsulfonylbenzenesulfonamide
molecule (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B,
top). The freezing of the select torsions was necessary because the
DFT calculation lacks the protein environment that keeps them at certain
values seen in docking. The energy difference between the lowest energy
and the docked conformers in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B was 53.8 kJ/mol. It became clear that the used scoring
function did not report a correct binding energy of the conformation
in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>A because
the Vinardo scoring function neither takes into account the change
of the ligand conformation when going from the solution into the receptor,
nor the ligand intramolecular energy (in fact, none of the several
built-in scoring functions in Smina do). This means that in the conformation
shown in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>A
the 2-methylsulfonyl group must rotate to avoid the rather severe
clash with the sulfonamide oxygens (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B, top), and by doing so the hydrophobic
substituent rotates away from Phe131, potentially yielding other clashes
with the protein and leading to the poor binding energies.</p><p>Series <bold>7</bold> compounds are more complex to investigate
because two enantiomers of the S atom of sulfinyl exist (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>C,D). We will explore
the behavior of sulfinyl-containing series <bold>7</bold> using compound <bold>7a</bold> as an example. One of its docked enantiomers, <italic toggle="yes">(S)</italic>-<bold>7a</bold> forms sulfonyl-sulfinyl clash (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>C and the top left part of <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>D) similar to what
we found for <bold>9a</bold>. The docked <italic toggle="yes">(R)</italic>-<bold>7a</bold> enantiomer is about 1.7 times more stable compared to the <italic toggle="yes">(S)-</italic> enantiomer because of the lack of the clash (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>D,F). Calculations
also show that in the absence of the protein, the preferred conformation <bold>7a</bold> (of either chirality) has an intramolecular H-bond (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>D,F, bottom).</p><p>For comparison, we also used DFT calculations of the 2-methylsulfanylbenzenesulfonamide
molecule to estimate the stability of the docked <bold>4a</bold> (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>G), which does not
seem to exhibit clashes. Comparison of <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B,D,F,H shows that the docked conformer <bold>4a</bold> is &#8764;1.5 times more stable than the most stable docked
conformer of <bold>7a</bold> and nearly 3 times more stable than docked <bold>9a</bold>, corresponding to the experimentally determined binding
affinities that are best in series <bold>4</bold>, followed by <bold>7</bold> and <bold>9</bold>. Interestingly, calculations suggest
that one reason for the relative stability of docked <bold>4</bold> is the lack of the intramolecular hydrogen bond in solution (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>H, bottom), and this
observation could be potentially used in designing better binders
for carbonic anhydrases, or even other receptors.</p></sec></sec></sec><sec id="sec3"><title>Discussion</title><p>Recognition of the pockets on the protein
surface by small-molecule
ligands is still rather poorly understood, and it is not possible
to accurately calculate the thermodynamic binding parameters.<xref rid="ref41" ref-type="bibr"/> Primary sulfonamide compounds are known to inhibit
CA isozymes by binding to the catalytic Zn&#173;(II). Chemical variation
of the remaining molecule often has a limited influence on binding
affinity and selectivity. However, some chemical changes made near
the sulfonamide group have a significant impact and may change the
behavior from strong binder to completely undetectable binding. To
investigate this phenomenon, we synthesized <italic toggle="yes">ortho</italic>-substituted benzenesulfonamides, determined their binding affinity
to all catalytically active isoforms of human carbonic anhydrases,
obtained crystal structures with CAII, CAIX, and CAXIII, and performed
molecular docking. Different oxidation forms of the linker at the <italic toggle="yes">ortho</italic> position were used: &#8722;S&#8211;, &#8722;SO&#8211;,
and &#8722;SO<sub>2</sub>&#8211;. Compounds with &#8722;SO&#8211;
or &#8722;SO<sub>2</sub>&#8211; linker were much weaker binders
to any CA isozyme than compounds with the &#8722;S&#8211; linker.
Several reasons could cause this. First, a substituent with a higher
oxidation state exhibits a stronger electron-withdrawing effect, thus
lowering the p<italic toggle="yes">K</italic>
<sub>a</sub> of the amine of the sulfonamide
group and causing stronger binding. Second, the linker oxygen atoms
may prevent the easier rotation of the ligand molecule bonds and prevent
conformational changes needed for the ligand to adapt to the protein
surface. Third, the oxygen atoms take additional space, and the steric
hindrance could be an essential factor in diminishing the binding
affinity.</p><p>To test the electron-withdrawing effect, the p<italic toggle="yes">K</italic>
<sub>a</sub> values of compounds were determined experimentally.
The p<italic toggle="yes">K</italic>
<sub>a</sub> of compounds containing &#8722;S&#8211;
linker was almost an entire pH unit higher than compounds with linkers
&#8722;SO&#8211; or &#8722;SO<sub>2</sub>&#8211;. Sulfonamides
bind to CA in their negatively charged deprotonated form.<xref rid="ref42" ref-type="bibr"/> Therefore, the lowering of sulfonamide p<italic toggle="yes">K</italic>
<sub>a</sub> increases the fraction of the binding-ready
deprotonated sulfonamide and thus increases the observed affinity.
This effect is simply the effect of compound availability in the proper
form. To eliminate this misleading increase in affinity, we subtract
the fraction effects and calculate the <italic toggle="yes">intrinsic</italic> affinity.
The intrinsic dissociation constants of all compounds are provided
next to the observed values in the table. In all cases, the intrinsic
affinities are higher than the observed ones. The intrinsic values
show the &#8216;real&#8217; affinities between the binding components
in the binding-ready protonation state. These values should be used
in drug design to explain the structure&#8211;function relationship
of the compound effects and not the experimentally observed ones.
However, the experimentally observed affinity values show the affinities
observed by any experimental technique, and the values are biologically
relevant. They should be used to calculate the bound fractions and
drug effect at particular conditions.</p><p>Furthermore, the compounds
with a higher oxidation state (<bold>7a, b, h, i, k&#8211;m</bold> and <bold>9a&#8211;d, h, i, l, m</bold>) did not bind or bind with
lower affinity than compounds <bold>4a&#8211;d,
f&#8211;m</bold>. Even the compounds <bold>7h</bold> and <bold>9h</bold> with the smallest methyl substituent did not match the sulfanyl
compound <bold>4h</bold> in affinity. The main reason for this was
the allowed conformations of the compounds, which were calculated
using quantum Density Functional Theory (DFT). The oxygen atoms limited
both the flexibility of the molecule in finding the optimal position
and acted as a steric hindrance. The present study shows that the <italic toggle="yes">ortho</italic> modifications had a more significant effect than the <italic toggle="yes">para</italic> variations.<xref rid="ref21" ref-type="bibr"/>
</p><p>The
highest affinity for CAIX in this study was exhibited by compound <bold>4b</bold> (methyl 4-cyclohexylsulfanyl-3-sulfamoylbenzoate). Previously
we have designed similar compounds bearing 2-chloro or 2-bromo substituents
that exhibited slightly higher affinity for CAIX.<xref rid="ref20" ref-type="bibr"/> Here, we have intentionally omitted the halogen atoms to
synthesize the <italic toggle="yes">ortho</italic>-substituted compounds more easily
and explore the binding without halogens. It was also easier to synthesize
compounds with an amide substituent in the <italic toggle="yes">meta</italic> position.
The length of these amide-substituted compounds was of limited importance
in the previous study but had a significant influence on this study,
likely due to reasons of steric hindrance.</p><p>Sulfonamide compounds
usually bind to CA isozymes by forming a
coordination bond between the Zn&#173;(II) and sulfonamide amino groups.
This bond significantly increases the affinity, but is not necessary
for binding to occur.<xref rid="ref43" ref-type="bibr"/> Removal of the
metal or change of the metal with another demonstrated that the coordination
bond contribution is additive and metal-dependent. Strongly binding
compounds like brinzolamide to CAII also bind to the Zn-free apoCAII.
The energy contribution of the coordination bond could be determined
by using a metal-exchange approach.</p><p>In the crystal structure
of compound <bold>4h</bold> bound to CAII,
two well-resolved compound molecules were bound in the active site.
The first was bound in a conventional way forming a coordination bond
with the Zn&#173;(II), but the second was bound to the protein residues
without forming a coordination bond with the Zn&#173;(II). This second compound
molecule did not bind solely due to crystal-forming effects because
it did not bind to the second protein molecule. Therefore, the binding
of the second molecule is likely not an artifact. However, the presence
of the second molecule in the crystal structure does not mean that
it is bound as strongly, nor that we can measure its binding affinity
experimentally. Binding assays showed that the stoichiometry here
was 1:1, and the affinity of the second molecule was likely weak compared
to the first one. Compound concentration in the crystallization experiments
was relatively high, millimolar, thus the second molecule could be
seen in the crystal structure even if the <italic toggle="yes">K</italic>
<sub>d</sub> was in the millimolar range and therefore not interfering in any
binding assays. This also means that the second molecule is biologically
irrelevant and would not play an essential role in drug design.</p></sec><sec id="sec4"><title>Conclusions</title><p>The strategy to acidify the p<italic toggle="yes">K</italic>
<sub>a</sub> of <italic toggle="yes">ortho</italic> sulfanyl-substituted benzenesulfonamides
by oxidation,
with the goal of increased affinity to CA, yielded an unexpected drop
of affinity in the order of hundreds of thousands of times. Small
changes in chemical structures influenced the flexibility of the molecule&#8217;s
substituents and steric restrictions on interactions with proteins.
Furthermore, some minor changes led to the discovery of novel CAIX
inhibitors with high affinity and selectivity.</p></sec><sec id="sec5"><title>Experimental Section</title><sec id="sec5.1"><title>Organic Synthesis</title><p>All starting materials and reagents
were commercial products used without further purification. Melting
points of the compounds were determined in open capillaries on a Thermo
Scientific 9100 Series and are uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S7</ext-link>) were
recorded on a (400 and 100 MHz, respectively) spectrometer in DMSO-<italic toggle="yes">d</italic>
<sub>6</sub> using residual DMSO signals (2.52 and 40.21
ppm for <sup>1</sup>H and <sup>13</sup>C NMR spectra, respectively)
as the internal standard. TLC was performed with silica gel 60 F254
aluminum plates (Merck) and visualized with UV light. Column chromatography
used silica gel 60 (0.040&#8211;0.063 mm, Merck). High-resolution
mass spectra (HRMS) were recorded by an Agilent TOF 6230 equipped
with an Agilent Infinity 1260 HPLC system (Agilent Technologies).
HPLC verified the purity of final compounds to be &gt;95% (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S8</ext-link>) using the Agilent Infinity 1260 instrument
with a ZORBAX Eclipse Plus C18 Rapid Resolution 4.6 &#215; 100 mm
3.5 &#956;m column, ZORBAX Eclipse Plus-C18 4.6 &#215; 12.5 mm 5.0
&#956;m analytical guard column, eluents A &#8211; 20 mM ammonium
acetate (pH = 6.9 of unadjusted solution) and B &#8211; 100% MeOH
was used. HPLC gradient elution with a flow rate of 0.80 mL/min was
used, B gradient: 0&#8211;10 min 55&#8211;95%, 10&#8211;14 min
95%. UV detection was recorded at 254 nm. <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S9</ext-link> contains ESI-MS spectra of representative compounds.</p><sec id="sec5.1.1"><title>Methyl 4-Chloro-3-sulfamoyl-benzoate (<bold>2</bold>)</title><p>4-chloro-3-sulfamoylbenzoic acid <bold>1</bold> (1.78 g, 7.55 mmol,
Sigma-Aldrich) was refluxed in MeOH (30 mL) with concentrated H<sub>2</sub>SO<sub>4</sub> (0.3 mL) for 8 h. The reaction mixture was
concentrated under reduced pressure. Residue was filtered, washed
with H<sub>2</sub>O and crystallized from H<sub>2</sub>O:MeOH&#173;(4:1).
Yield: 1.70 g, 91%, mp 129&#8211;130 &#176;C (Literature<xref rid="ref44" ref-type="bibr"/> mp 124&#8211;125 &#176;C).</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.91 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.80 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 7.84 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.14 (dd, <italic toggle="yes">J</italic> = 8.4 Hz, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, Ar<bold>H</bold>), 8.52 (d, <italic toggle="yes">J</italic> = 2.1
Hz, 1H, Ar<bold>H</bold>).</p></sec><sec id="sec5.1.2"><title>
<italic toggle="yes">N</italic>-Butyl-4-chloro-3-sulfamoyl-benzamide (<bold>3</bold>)</title><p>The mixture of 4-chloro-3-sulfamoylbenzoic acid <bold>1</bold> (500 mg, 2.12 mmol), SOCl<sub>2</sub> (0.616 mL, 8.48 mmol),
and one drop DMF in toluene (6.0 mL) was refluxed for four h. Excess
SOCl<sub>2</sub> and toluene were removed by distillation under reduced
pressure. The crude acid chloride was dissolved in THF (20 mL) and
added dropwise to a solution of <italic toggle="yes">N</italic>-butylamine (0.591
mL, 6.0 mmol) in THF (20 mL) at 0 &#176;C and allowed stirring for
one h. The mixture was warmed to room temperature and stirred for
another 4 h. THF was removed under reduced pressure. The crude product
was crystallized from H<sub>2</sub>O. Yield: 492 mg, 80%, mp 172&#8211;173
&#176;C (lit.<xref rid="ref45" ref-type="bibr"/> mp 171&#8211;172 &#176;C).</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.92 (t, <italic toggle="yes">J</italic> =
7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>CH<sub>2</sub>), 1.37 (sextet, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.54 (quint, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, CH<sub>2</sub>
<bold>CH</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 3.29 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 7.72 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.77 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H, Ar<bold>H</bold>), 8.04 (dd, <italic toggle="yes">J</italic> =
8.2 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.45 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.77 (t, <italic toggle="yes">J</italic> = 5.5 Hz, 1H, N<bold>H</bold>).</p></sec><sec id="sec5.1.3"><title>General Procedure for the syntheses of <bold>4a&#8211;d, f,
g, i&#8211;m</bold>
</title><p>The mixture of methyl 4-chloro-3-sulfamoylbenzoate <bold>2</bold> (285 mg, 1,14 mmol), DMF (4.0 mL), appropriate thiol (1.25
mmol), and K<sub>2</sub>CO<sub>3</sub> (630 mg, 4,56 mmol) was heated
at 80 &#176;C for 4&#8211;6 h in an inert atmosphere (argon). The
mixture was cooled to room temperature, and 10 mL of H<sub>2</sub>O was added. The product was extracted with EtOAc (3 &#215; 8 mL).
The organic layer was washed with H<sub>2</sub>O, dried over anhydrous
MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure.</p></sec><sec id="sec5.1.4"><title>Methyl 4-Phenylsulfanyl-3-sulfamoyl-benzoate (<bold>4a</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 6:1). Yield: 303 mg, 82%, mp 155&#8211;156
&#176;C. (lit.<xref rid="ref46" ref-type="bibr"/> mp 154&#8211;157).</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.86 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.00 (d, <italic toggle="yes">J</italic> = 8.4 Hz,
1H, Ar<bold>H</bold>), 7.55&#8211;7.62 (m, 5H, Ar<bold>H</bold>),
7.74 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.93 (dd, <italic toggle="yes">J</italic> = 8.4 Hz, <italic toggle="yes">J</italic> = 1.9
Hz, 1H, Ar<bold>H</bold>), 8.46 (t, <italic toggle="yes">J</italic> = 1.9 Hz, 1H,
Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 52.9,
126.8, 129.0, 129.2, 130.5,
130.8, 131.0, 132.6, 135.5, 140.8, 144.2, 165.4.</p><p>HRMS calcd
for C<sub>14</sub>H<sub>13</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 324.0359, found: 324.0354.</p></sec><sec id="sec5.1.5"><title>Methyl 4-Cyclohexylsulfanyl-3-sulfamoyl-benzoate (<bold>4b</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 7:1). Yield: 315 mg, 84%, mp 119&#8211;120
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.26&#8211;1.99
(m, 10H, C<bold>H</bold> cyclohexyl), 3.61 (m, 1H, C<bold>H</bold>S), 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.47
(s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.74
(d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 8.04 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, Ar<bold>H</bold>), 8.43 (d, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 25.7, 25.8, 32.5, 44.4, 52.9,
100.0, 125.9, 129.1, 132.3, 141.7, 142.8, 165.6.</p><p>HRMS calcd
for C<sub>14</sub>H<sub>19</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 330.0828, found: 330.0833.</p></sec><sec id="sec5.1.6"><title>Methyl 4-Benzylsulfanyl-3-sulfamoyl-benzoate (<bold>4c</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 6:1). Yield: 211 mg, 55%, mp 135&#8211;136
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 4.43 (s, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 7.29&#8211;7.37 (m, 3H, Ar<bold>H</bold>), 7.51&#8211;7.53 (m, 2H, Ar<bold>H</bold>), 7.58 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.74 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 8.02 (dt, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.42
(t, <italic toggle="yes">J</italic> = 2.2 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 36.4, 52.9, 125.9, 127.7, 128.0,
128.9, 129.0, 129.8, 132.2, 136.0, 140.7, 143.7, 165.6.</p><p>HRMS
calcd for C<sub>15</sub>H<sub>15</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 338.0515, found: 338.0517.</p></sec><sec id="sec5.1.7"><title>Methyl 4-(2-Phenylethylsulfanyl)-3-sulfamoyl-benzoate (<bold>4d</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 332 mg, 83%, mp
146&#8211;147 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 2.99
(t, <italic toggle="yes">J</italic> = 7.5 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>Ph), 3.41 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.23&#8211;7.34 (m, 5H, Ar<bold>H</bold>), 7.51
(s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.73
(d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 8.05 (dd, <italic toggle="yes">J</italic> = 8.4 Hz, <italic toggle="yes">J</italic> = 1.8 Hz, 1H, Ar<bold>H</bold>), 8.43 (d, <italic toggle="yes">J</italic> = 1.8 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 33.4, 34.3, 52.9, 125.8, 126.9,
127.8, 128.8, 128.9, 129.1, 132.4, 140.2, 141.,0, 143.6, 165.6.</p><p>HRMS calcd for C<sub>16</sub>H<sub>17</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 352.0672, found: 352.0675.</p></sec><sec id="sec5.1.8"><title>Methyl 4-Cyclododecylsulfanyl-3-sulfamoyl-benzoate (<bold>4f</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 10:1). Yield: 203 mg, 43%, mp 167&#8211;168
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.32&#8211;1.59
(m, 20H, C<bold>H</bold> cyclododecyl), 1.76 (m, 2H, C<bold>H</bold> cyclododecyl), 3.66 (m, 1H, C<bold>H</bold>S), 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.47 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.70 (d, <italic toggle="yes">J</italic> =
8.4 Hz, 1H, Ar<bold>H</bold>), 8.07 (dd, <italic toggle="yes">J</italic> = 8.4
Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.44 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 22.0, 23.2, 23.3, 24.0, 24.2,
29.2, 43.5, 52.9, 125.9, 129.0, 129.2, 132.3, 142.0, 143.2, 165.6.</p><p>HRMS calcd for C<sub>20</sub>H<sub>31</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 414.1767, found: 414.1773.</p></sec><sec id="sec5.1.9"><title>Methyl 4-(1-Adamantylsulfanyl)-3-sulfamoyl-benzoate (<bold>4g</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 10:1). Yield: 173 mg, 40%, mp 189&#8211;190
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.63 (br s, 6H,
C<bold>H</bold> adamantanyl), 1.98 (br s, 6H, C<bold>H</bold> adamantanyl),
2.00 (br s, 3H, C<bold>H</bold> adamantanyl), 3.90 (s, 3H, OC<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 7.40 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.87 (d, <italic toggle="yes">J</italic> =
8.0 Hz, 1H, Ar<bold>H</bold>), 8.08 (dd, <italic toggle="yes">J</italic> = 8.0
Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.53 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 30.1, 35.9, 43.8, 52.2, 53.0,
128.8, 128.9, 131.8, 137.7, 137.9, 147.0, 165.5.</p><p>HRMS calcd
for C<sub>18</sub>H<sub>23</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 382.1141, found: 382.1144.</p></sec><sec id="sec5.1.10"><title>Methyl 4-Propylsulfanyl-3-sulfamoyl-benzoate (<bold>4i</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 202 mg, 61%, mp 111&#8211;112
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.05 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>CH<sub>2</sub>), 1.71 (quint, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, CH<sub>3</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.11 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.54
(s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.65
(d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 8.04 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, Ar<bold>H</bold>), 8.43 (d, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 13.8, 21.7, 33.9, 52.8, 125.6,
127.5, 128.9, 132.3, 140.9, 144.1, 165.6.</p><p>HRMS calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 290.0515, found: 290.0519.</p></sec><sec id="sec5.1.11"><title>Methyl 4-<italic toggle="yes">tert</italic>-Butylsulfanyl-3-sulfamoyl-benzoate
(<bold>4j</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 214 mg, 62%, mp
124&#8211;125 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.43
(s, 9H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 3.90 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.43 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.91 (d, <italic toggle="yes">J</italic> =
8.2 Hz, 1H, Ar<bold>H</bold>), 8.11 (dd, <italic toggle="yes">J</italic> = 8.2
Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.52 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 31.6, 49.6, 53.0, 128.4, 128.9,
132.0, 136.2, 140.0, 146.1, 165.5.</p><p>HRMS calcd for C<sub>12</sub>H<sub>17</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 304.0672,
found: 304.0671.</p></sec><sec id="sec5.1.12"><title>Methyl 4-Isopentylsulfanyl-3-sulfamoyl-benzoate (<bold>4k</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 265 mg, 74%, mp 92&#8211;93
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.94 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 6H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.57 (td, <italic toggle="yes">J</italic> = 7.8 Hz, <italic toggle="yes">J</italic> = 6.8
Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH), 1.76 (m, 1H,
C<bold>H</bold>), 3.11 (t, <italic toggle="yes">J</italic> = 7.8 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 3.88 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.52 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.67 (d, <italic toggle="yes">J</italic> = 8.4 Hz,
Ar<bold>H</bold>), 8.05 (dd, <italic toggle="yes">J</italic> = 8.4 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.42 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 22.6, 27.5, 30.2, 36.9, 52.8,
125.6, 127.5, 128.9, 132.3, 140.9, 144.1, 165.6.</p><p>HRMS calcd
for C<sub>13</sub>H<sub>19</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 318.0828, found: 318.0833.</p></sec><sec id="sec5.1.13"><title>Methyl 4-Cyclopentylsulfanyl-3-sulfamoyl-benzoate (<bold>4l</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 8:1). Yield: 259 mg, 72%, mp 106&#8211;107
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.55&#8211;1.65
(m, 4H, C<bold>H</bold> cyclopentyl), 1.73&#8211;1.78 (m, 2H, C<bold>H</bold> cyclopentyl), 2.18&#8211;2.23 (m, 2H, C<bold>H</bold> cyclopentyl),
3.84&#8211;3.92 (m, 4H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O
and C<bold>H</bold>S), 7.50 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.72 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H,
Ar<bold>H</bold>), 8,.04 (dd, <italic toggle="yes">J</italic> = 8.4 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.42 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 25.1, 33.3, 43.9, 52.8, 125.5,
128.4, 128.9, 132.3, 140.8, 144.7, 165.6.</p><p>HRMS calcd for C<sub>13</sub>H<sub>17</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 316.0672, found: 316.0677.</p></sec><sec id="sec5.1.14"><title>Methyl 4-(1-Naphthylsulfanyl)-3-sulfamoyl-benzoate (<bold>4m</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 8:1). Yield: 281 mg, 66%, mp 187&#8211;188
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.83 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 6.64 (d, <italic toggle="yes">J</italic> =
8.4 Hz, 1H, Ar<bold>H</bold>), 7.54&#8211;7.64 (m, 2H, Ar<bold>H</bold>), 7.69 (m, 1H, Ar<bold>H</bold>), 7.74 (dd, <italic toggle="yes">J</italic> =
8.4 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 7.93 (s,
2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.04&#8211;8.15
(m, 3H, Ar<bold>H</bold>), 8.22 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H,
Ar<bold>H</bold>), 8.49 (d, <italic toggle="yes">J</italic> = 2.,0 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 52.9, 125.6,
126.7, 126.9, 127.3,
127.5, 128.4, 128.5, 129.1, 129.6, 132.2, 132.5, 133.8, 134.8, 136.8,
140.4, 143.9, 165.4.</p><p>HRMS calcd for C<sub>18</sub>H<sub>15</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 374.0515, found:
374.0511.</p></sec><sec id="sec5.1.15"><title>Methyl 4-Methylsulfanyl-3-sulfamoyl-benzoate (<bold>4h</bold>)</title><p>The mixture of methyl 4-chloro-3-sulfamoylbenzoate <bold>2</bold> (308 mg, 1,23 mmol), DMSO (4.0 mL), sodium methanethiolate
(259 mg, 3.69 mmol), and K<sub>2</sub>CO<sub>3</sub> (509 mg, 3.69
mmol) was heated at 80 &#176;C temperature for 12 h in inert atmosphere&#173;(argon).
The mixture was cooled to room temperature and 20 mL brine was added.
The product was extracted with EtOAc (3 &#215; 10 mL). The organic
layer was washed with H<sub>2</sub>O, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product
was crystallized from H<sub>2</sub>O:MeOH&#173;(4:1). Yield: 203 mg, 64%,
mp 157&#8211;158 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H
NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 2.59 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>S), 3.89
(s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.54 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.61 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 8.07 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.4 Hz, 1H, Ar<bold>H</bold>), 8.42
(d, <italic toggle="yes">J</italic> = 1.4 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 15.5, 52.9, 125.4, 126.6, 128.8,
132.4, 140.4, 145.1, 165.7.</p><p>HRMS calcd for C<sub>9</sub>H<sub>11</sub>NO<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 262.0202,
found: 262.0199.</p></sec><sec id="sec5.1.16"><title>General Procedure for the Syntheses of <bold>5a&#8211;d, f&#8211;g,
j&#8211;m</bold>
</title><p>The mixture of <italic toggle="yes">N</italic>-butyl-4-chloro-3-sulfamoyl-benzamide <bold>3</bold> (111 mg, 0.381 mmol), DMF (4.0 mL), appropriate thiol (0.572
mmol), and K<sub>2</sub>CO<sub>3</sub> (210 mg, 1.52 mmol) was heated
at 80 &#176;C temperature for 12 h in an inert atmosphere&#173;(argon).
The mixture was cooled to room temperature and 20 mL H<sub>2</sub>O was added. The product was extracted with EtOAc (3 &#215; 8 mL).
The organic layer was washed with H<sub>2</sub>O, dried over anhydrous
MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure.</p></sec><sec id="sec5.1.17"><title>
<italic toggle="yes">N</italic>-Butyl-4-phenylsulfanyl-3-sulfamoyl-benzamide
(<bold>5a</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 71 mg, 51%, mp
109&#8211;110 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.90
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.33 (sext, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.52 (quint, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 3.27 (dt, <italic toggle="yes">J</italic> = 6.9
Hz, <italic toggle="yes">J</italic> = 5.7 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 6.99 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 7.51&#8211;7.58 (m, 5H, Ar<bold>H</bold>), 7.60 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.82 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.38 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.59
(t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 31.6, 39.4, 127.5,
129.6, 129.9, 130.5, 130.6, 132.3, 132.4, 134.9, 140.7, 141.2, 164.9.</p><p>HRMS calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 365.0988, found: 365.0985.</p></sec><sec id="sec5.1.18"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclohexylsulfanyl-3-sulfamoyl-benzamide
(<bold>5b</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 70 mg, 50%, mp
114&#8211;115 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.92
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.23&#8211;1.63 (m, 10H, C<bold>H</bold> cyclohexyl and
butyl), 1.72 (m, 2H, C<bold>H</bold> cyclohexyl), 1.90&#8211;1.96
(m, 2H, C<bold>H</bold> cyclohexyl), 3.29 (q, <italic toggle="yes">J</italic> =
6.6 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.55&#8211;3.60
(m, 1H, C<bold>H</bold>S), 7.34 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.70 (d, <italic toggle="yes">J</italic> = 8.2 Hz,
1H, Ar<bold>H</bold>), 7.96 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.2 Hz, 1H, Ar<bold>H</bold>), 8.36 (d, <italic toggle="yes">J</italic> = 1.2 Hz, 1H, Ar<bold>H</bold>), 8.64 (t, <italic toggle="yes">J</italic> = 5.3
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 25.7, 25.8, 31.6,
32.5, 39.4, 44.8, 127.6, 129.7, 130.3, 131.6, 139.0, 142.1, 165.1</p><p>HRMS calcd for C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 371.1458, found: 371.1463.</p></sec><sec id="sec5.1.19"><title>4-Benzylsulfanyl-<italic toggle="yes">N</italic>-butyl-3-sulfamoyl-benzamide
(<bold>5c</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 65 mg, 45%, mp
185&#8211;186 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.36 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.53 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, CH<sub>2</sub>
<bold>CH</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 3.28 (q, <italic toggle="yes">J</italic> = 6.9 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 4.40 (s, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 7.29 (t, <italic toggle="yes">J</italic> = 7.1 Hz,
1H, Ar<bold>H</bold>), 7.36 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 2H, Ar<bold>H</bold>), 7.44 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.52 (d, <italic toggle="yes">J</italic> = 7.1 Hz, 2H, Ar<bold>H</bold>), 7.66 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 7.94
(dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.9 Hz, 1H,
Ar<bold>H</bold>), 8.36 (d, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, Ar<bold>H</bold>), 8.62 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 31.6, 36.5, 39.4,
127.6, 127.7, 127.8, 128.9, 129.7, 130.2, 131.2, 136.5, 140.2, 140.7,
165.0.</p><p>HRMS calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 379.1145, found:
379.1140.</p></sec><sec id="sec5.1.20"><title>
<italic toggle="yes">N</italic>-Butyl-4-(2-phenylethylsulfanyl)-3-sulfamoyl-benzamide
(<bold>5d</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 95 mg, 63%, mp
116&#8211;117 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.92
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.37 (sext, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.55 (quint, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 2.98 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>Ar), 3.28 (q, <italic toggle="yes">J</italic> = 6.6 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.34&#8211;3.38
(m, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>S), 7.25&#8211;7.27
(m, 1H, Ar<bold>H</bold>), 7.31&#8211;7.33 (m, 4H, Ar<bold>H</bold>), 7.35 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.69 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 7.99
(d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, Ar<bold>H</bold>), 8.38 (s, 1H,
Ar<bold>H</bold>), 8.65 (t, <italic toggle="yes">J</italic> = 5.4 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1,
31.6, 33.7, 34.4,
39.4, 126.9, 127.5, 127.9, 128.9, 129.0, 130.4, 131.3, 140.1, 140.3,
141.2, 165.1.</p><p>HRMS calcd for C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 393.1301,
found: 393.1297.</p></sec><sec id="sec5.1.21"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclododecylsulfanyl-3-sulfamoyl-benzamide
(<bold>5f</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 3:1). Yield: 76 mg, 44%, mp
166&#8211;168 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.93
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.24&#8211;1.59 (m, 24H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub> and
C<bold>H</bold> cyclododecyl), 1.72&#8211;1.75 (m, 2H, C<bold>H</bold> cyclododecyl), 3.29 (dt, <italic toggle="yes">J</italic> = 6.8 Hz, <italic toggle="yes">J</italic> = 5.6 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.68
(s, 1H, C<bold>H</bold>S), 7.33 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.66 (d, <italic toggle="yes">J</italic> = 8.3 Hz,
1H, Ar<bold>H</bold>), 7.99 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.37 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.64 (t, <italic toggle="yes">J</italic> = 5.6
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 22.1, 23.4, 23.8,
23.9, 24.2, 29.4, 31.6, 39.4, 43.7, 127.6, 129.5, 130.3, 131.6, 139.7,
142.3, 165.1.</p><p>HRMS calcd for C<sub>23</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 455.2397,
found: 455.2399.</p></sec><sec id="sec5.1.22"><title>4-(1-Adamantylsulfanyl)-<italic toggle="yes">N</italic>-butyl-3-sulfamoyl-benzamide
(<bold>5g</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 64 mg, 40%, mp
187&#8211;189 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91
(t, <italic toggle="yes">J</italic> = 6.8 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.34 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.52 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 1.63 (br s, 6H, C<bold>H</bold> adamantanyl), 1.95 (br s,
6H, C<bold>H</bold> adamantanyl), 2.01 (br s, 3H, C<bold>H</bold> adamantanyl),
3.28 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.28 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.78 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 7.98 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.44 (d, <italic toggle="yes">J</italic> = 2.0
Hz, 1H, Ar<bold>H</bold>), 8.71 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H,
N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2,
20.1, 30.1, 31.6, 36.0,
39.5, 43.9, 51.8, 127.4, 129.8, 134.0, 134.5, 138.2, 147.3, 165.2.</p><p>HRMS calcd for C<sub>21</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 423.1771, found: 423.1777.</p></sec><sec id="sec5.1.23"><title>
<italic toggle="yes">N</italic>-Butyl-4-<italic toggle="yes">tert</italic>-butylsulfanyl-3-sulfamoyl-benzamide
(<bold>5j</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 55 mg, 42%, mp
150&#8211;152 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91
(t, <italic toggle="yes">J</italic> = 7.6 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.30&#8211;1.37 (m, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.41 (s, 9H, C&#173;(C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>)<sub>3</sub>), 1.52 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.28 (q, <italic toggle="yes">J</italic> = 6.0 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.31 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.82 (d, <italic toggle="yes">J</italic> = 7.6 Hz,
1H, Ar<bold>H</bold>), 7.99 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.44 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.71 (t, <italic toggle="yes">J</italic> = 5.8
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 31.6, 31.7, 39.5,
49.4, 127.5, 130.1, 134.3, 136.2, 137.0, 146.7, 165.2.</p><p>HRMS
calcd for C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 345.1301, found: 345.1295.</p></sec><sec id="sec5.1.24"><title>
<italic toggle="yes">N</italic>-Butyl-4-isopentylsulfanyl-3-sulfamoyl-benzamide
(<bold>5k</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 98 mg, 72%, mp
130&#8211;132 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.89&#8211;0.94
(m, 9H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.33 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.48&#8211;1.57 (m, 4H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub> and SCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 1.75 (hept, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, C<bold>H</bold>(CH<sub>3</sub>)<sub>2</sub>), 3.09
(t, <italic toggle="yes">J</italic> = 7.8 Hz, 2H, SC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.30 (q, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.38 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.61 (d, <italic toggle="yes">J</italic> = 8.4 Hz,
1H, Ar<bold>H</bold>), 7.97 (dd, <italic toggle="yes">J</italic> = 8.3 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.36 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.62 (t, <italic toggle="yes">J</italic> = 5.3
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 22.6, 27.5, 30.4,
31.7, 37.2, 39.4, 127.6&#173;(2C), 130.4, 131.1, 140.6, 141.0, 165.1.</p><p>HRMS calcd for C<sub>16</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 359.1458, found: 359.1464.</p></sec><sec id="sec5.1.25"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclopentylsulfanyl-3-sulfamoyl-benzamide
(<bold>5l</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 84 mg, 62%, mp
122&#8211;124 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.33 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.48&#8211;1.67
(m, 6H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub> and
C<bold>H</bold> cyclopentyl), 1.71&#8211;1.81 (m, 2H, C<bold>H</bold> cyclopentyl), 2.12&#8211;2.21 (m, 2H, C<bold>H</bold> cyclopentyl),
3.28 (q, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.92 (quint, <italic toggle="yes">J</italic> = 6.0 Hz, 1H, SC<bold>H</bold>), 7.36 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.66 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 7.96 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, Ar<bold>H</bold>), 8.36
(s, 1H, Ar<bold>H</bold>), 8.61 (t, <italic toggle="yes">J</italic> = 5.2 Hz, 1H,
N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2,
20.1, 25.1, 31.7, 33.3,
39.4, 44.2, 127.6, 128.5, 130.3, 131.0, 141.0, 141.2, 165.1.</p><p>HRMS calcd for C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 357.1301, found: 357.1307.</p></sec><sec id="sec5.1.26"><title>
<italic toggle="yes">N</italic>-Butyl-4-(1-naphthylsulfanyl)-3-sulfamoyl-benzamide
(<bold>5m</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 96 mg, 61%, mp
216&#8211;218 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: (DMSO&#8211;D<sub>6</sub>): 0.86 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.28 (sext, <italic toggle="yes">J</italic> = 7.6
Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.45 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.21 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 6.57 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 7.53&#8211;7.63
(m, 3H, Ar<bold>H</bold> and, naphthyl-<bold>H</bold>), 7.68 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, naphthyl-<bold>H</bold>), 7.83 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.03 (d, <italic toggle="yes">J</italic> = 6.8 Hz, 1H, naphthyl-<bold>H</bold>), 8.08 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, naphthyl-<bold>H</bold>), 8.15 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, naphthyl-<bold>H</bold>), 8.19 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, naphthyl-<bold>H</bold>), 8.41 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.50 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 14.1, 20.0, 31.6, 39.4, 125.8,
126.9, 127.4, 127.7, 128.1, 128.2&#173;(2C), 129.5, 130.4, 131.8, 132.1,
133.7, 134.8, 136.5, 140.4, 140.7, 165.1.</p><p>HRMS calcd for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 415.1145, found: 415.1151.</p></sec><sec id="sec5.1.27"><title>General Procedure for the Syntheses of <bold>6b, c, e</bold>
</title><p>The mixture of <italic toggle="yes">N</italic>-butyl-4-chloro-3-sulfamoyl-benzamide <bold>3</bold> (100 mg, 0.344 mmol) and appropriate amine (2.0 mL) was
heated at 130 &#176;C for 24 h in an inert atmosphere. The mixture
was cooled to room temperature and 2 N HCl&#173;(aq) (5 mL) was added. The
product was extracted with EtOAc (3 &#215; 5 mL). The organic layer
was washed with H<sub>2</sub>O, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure.</p></sec><sec id="sec5.1.28"><title>
<italic toggle="yes">N</italic>-Butyl-4-(cyclohexylamino)-3-sulfamoyl-benzamide
(<bold>6b</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 64 mg, 53%, mp
89&#8211;91 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.23&#8211;1.60 (m, 10H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub> and
C<bold>H</bold> cyclohexyl), 1.66&#8211;1.69 (m, 2H, C<bold>H</bold> cyclohexyl), 1.90&#8211;1.93 (m, 2H, C<bold>H</bold> cyclohexyl),
3.25 (dt, <italic toggle="yes">J</italic> = 6.8 Hz, <italic toggle="yes">J</italic> = 5.7 Hz,
2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.49&#8211;3.52
(m, 1H, C<bold>H</bold>NH), 6,17 (d, <italic toggle="yes">J</italic> = 7.6 Hz,
1H, N<bold>H</bold>-cyclohexyl), 6.84 (d, <italic toggle="yes">J</italic> = 8.8
Hz, 1H, Ar<bold>H</bold>), 7.43 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.85 (dd, <italic toggle="yes">J</italic> = 8.8 Hz, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, Ar<bold>H</bold>), 8.21 (d, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, Ar<bold>H</bold>), 8.25 (t, <italic toggle="yes">J</italic> = 5.7
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 24.4, 25.8, 31.9,
32.3, 39.2, 50.5, 111.8, 120.9, 124.5, 129.2, 132.3, 146.3, 165.4.</p><p>HRMS calcd for C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>S [(M+H)<sup>+</sup>]: 354.1846, found: 354.1840.</p></sec><sec id="sec5.1.29"><title>4-(Benzylamino)-<italic toggle="yes">N</italic>-butyl-3-sulfamoyl-benzamide
(<bold>6c</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 40 mg, 32%, mp
132&#8211;133 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.88
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.35 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.49 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 3.23 (dt, <italic toggle="yes">J</italic> = 6.8 Hz, <italic toggle="yes">J</italic> = 5.9 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 4.55
(d, <italic toggle="yes">J</italic> = 5.8 Hz, 2H, PhC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 6.69 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 1H, Ar<bold>H</bold>), 6.82 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H, N<bold>H</bold>-benzyl),
7.23&#8211;7.39 (m, 5H, Ar<bold>H</bold>), 7.49 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.77 (dd, <italic toggle="yes">J</italic> = 8.8 Hz, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, Ar<bold>H</bold>), 8.23
(m, 2H, Ar<bold>H</bold> and N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 31.8, 39.2, 46.5,
111.9, 121.5, 125.1, 127.4, 128.9, 128.9, 132.1, 139.2, 146.8, 165.4.</p><p>HRMS calcd for C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S [(M+H)<sup>+</sup>]: 362.1533, found: 362.1539.</p></sec><sec id="sec5.1.30"><title>
<italic toggle="yes">N</italic>-Butyl-4-(cyclooctylamino)-3-sulfamoyl-benzamide
(<bold>6e</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 55 mg, 42%, brownish
oily residue.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.91 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.35 (sext, <italic toggle="yes">J</italic> = 7.3 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.44&#8211;1.73 (m, 14H, C<bold>H</bold> cyclooctyl and CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 1.81&#8211;1.86 (m, 2H, C<bold>H</bold> cyclooctyl),
3.25 (dt, <italic toggle="yes">J</italic> = 6.9 Hz, <italic toggle="yes">J</italic> = 5.9 Hz,
2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.70&#8211;3.73
(m, 1H, C<bold>H</bold>NH cyclooctyl), 6.19 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, N<bold>H-</bold>cyclooctyl), 6.75 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 1H, Ar<bold>H</bold>), 7.43 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7,.86 (dd, <italic toggle="yes">J</italic> = 8.8 Hz, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, Ar<bold>H</bold>), 8.19
(d, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, Ar<bold>H</bold>), 8.24 (t, <italic toggle="yes">J</italic> = 5.9 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 23.6, 25.5, 27.2,
31.7, 31.9, 39.2, 51.9, 111.9, 120.8, 124.6, 129.3, 132.4, 146.1,
165.5.</p><p>HRMS calcd for C<sub>19</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub>S [(M+H)<sup>+</sup>]: 382.2159, found: 382.2155.</p></sec><sec id="sec5.1.31"><title>General Procedure for the Syntheses of <bold>7&#173;(a, b, h, i, k&#8211;m),
8&#173;(a, b, k&#8211;m)</bold>
</title><p>The mixture of appropriate methyl
4-sulfanilsubstituted-3-sulfamoyl-benzoate (<bold>4a, b, h, i, k&#8211;m</bold>) or appropriate <italic toggle="yes">N</italic>-butyl-4-sulfanilsubstituted-3-sulfamoyl-benzamide
(<bold>8a, b, k&#8211;m</bold>) (0.200 mmol), acetic acid (2.0 mL)
and 30% H<sub>2</sub>O<sub>2</sub> (0.090 mL, 1.15 mmol) was stirred
for 12 h. Then 1% Na<sub>2</sub>SO<sub>3</sub>(aq) (6.0 mL) was added
to the mixture and the product was extracted with EtOAc (3 &#215;
5 mL). The organic layer was washed with H<sub>2</sub>O, dried over
anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced
pressure.</p></sec><sec id="sec5.1.32"><title>Methyl 4-(Benzenesulfinyl)-3-sulfamoyl-benzoate (<bold>7a</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 3:1). Yield: 56 mg, 82%, mp 107&#8211;108
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3,91 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.48&#8211;7.53 (m, 3H, Ar<bold>H</bold>), 7.75&#8211;7.78 (m, 2H, Ar<bold>H</bold>), 8.09 (s, 2H,
SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.32 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H, Ar<bold>H</bold>), 8.37 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.47
(d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 53.3, 125.6, 126.9, 128.5, 129.9,
131.6, 132.8, 133.9, 142.3, 145.9, 149.7, 164.9.</p><p>HRMS calcd
for C<sub>14</sub>H<sub>13</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 340.0308, found: 340.0311.</p></sec><sec id="sec5.1.33"><title>Methyl 4-Cyclohexylsulfinyl-3-sulfamoyl-benzoate (<bold>7b</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 3:1). Yield: 52 mg, 75%, mp 188&#8211;189
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.14&#8211;2.07
(m, 10H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub> cyclohexyl), 2.96&#8211;3.04
(m, 1H, C<bold>H</bold>SO), 3.94 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.11 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H,
Ar<bold>H</bold>), 8.38 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.51 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 20.9, 25.1, 25.4, 26.1, 28.6,
53.3, 60.9, 127.3, 129.1, 132.5, 132.6, 142.1, 146.5, 165.1.</p><p>HRMS calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 346.0777, found: 346.0783.</p></sec><sec id="sec5.1.34"><title>Methyl 4-Methylsulfinyl-3-sulfamoyl-benzoate (<bold>7h</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 50 mg, 90%, mp 258&#8211;259
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 2.81 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>SO), 3.95 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.34 (d, <italic toggle="yes">J</italic> = 8.2 Hz,
1H, Ar<bold>H</bold>), 8.43 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.47 (d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 44.6, 53.3, 125.7, 128.5, 132.6,
133.8, 141.5, 151.2, 165.1.</p><p>HRMS calcd for C<sub>9</sub>H<sub>11</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 278.0151,
found: 278.0155.</p></sec><sec id="sec5.1.35"><title>Methyl 4-Propylsulfinyl-3-sulfamoyl-benzoate (<bold>7i</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 3:1). Yield: 40 mg, 66%, mp 144&#8211;145
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.99 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>CH<sub>2</sub>), 1.59&#8211;1.62 (m, 1H, C<bold>H</bold>
<sub>
<bold>A</bold>
</sub>H<sub>B</sub>CH<sub>3</sub>); 1,77&#8211;1.81 (m,
1H, CH<sub>A</sub>
<bold>H</bold>
<sub>
<bold>B</bold>
</sub>CH<sub>3</sub>), 2.66&#8211;2.69 (m, 1H, C<bold>H</bold>
<sub>
<bold>A</bold>
</sub>H<sub>B</sub>SO), 3.10&#8211;3.13 (m, 1H, CH<sub>A</sub>
<bold>H</bold>
<sub>
<bold>B</bold>
</sub>SO), 3.93 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.26 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H,
Ar<bold>H</bold>), 8.41 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.48 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 13.2, 16.5, 53.3, 58.9, 126.3,
128.7, 132.5, 133.4, 141.7, 149.2, 165.1.</p><p>HRMS calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 306.0464, found: 306.0470.</p></sec><sec id="sec5.1.36"><title>Methyl 4-Isopentylsulfinyl-3-sulfamoyl-benzoate (<bold>7k</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 37 mg, 55%, mp 98&#8211;99
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.86 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 0.89 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.40&#8211;1.45 (m, 1H, C<bold>H</bold>
<sub>
<bold>A</bold>
</sub>H<sub>B</sub>CH), 1.63&#8211;1.68 (m, 2H, C<bold>H</bold>CH<sub>3</sub> and CH<sub>A</sub>
<bold>H</bold>
<sub>
<bold>B</bold>
</sub>CH), 2.66&#8211;2.69 (m, 1H, C<bold>H</bold>
<sub>
<bold>A</bold>
</sub>H<sub>B</sub>SO), 3.15&#8211;3.19 (m, 1H, CH<sub>A</sub>
<bold>H</bold>
<sub>
<bold>B</bold>
</sub>SO), 3.94 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.26 (d, <italic toggle="yes">J</italic> = 8.2 Hz,
1H, Ar<bold>H</bold>), 8.41 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.49 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 22.4, 22.8, 27.2, 31.4, 53.3,
55.1, 126.4, 128.7, 132.5, 133.4, 141.7, 149.1, 165.1.</p><p>HRMS
calcd for C<sub>13</sub>H<sub>19</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 334.0777, found: 334.0771.</p></sec><sec id="sec5.1.37"><title>Methyl 4-Cyclopentylsulfinyl-3-sulfamoyl-benzoate (<bold>7l</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 4:1). Yield: 51 mg, 77%, mp 109&#8211;111
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.08&#8211;1.18
(m, 1H, C<bold>H</bold> cyclopentyl), 1.43&#8211;1.53 (m, 1H, C<bold>H</bold> cyclopentyl), 1.54&#8211;1.66 (m, 3H, C<bold>H</bold> cyclopentyl),
1.80&#8211;1.94 (m, 2H, C<bold>H</bold> cyclopentyl), 2.00&#8211;2.11
(m, 1H, C<bold>H</bold> cyclopentyl), 3.53 (quint, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, C<bold>H</bold> cyclopentyl), 3.94 (s, 3H, OC<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.16 (d, <italic toggle="yes">J</italic> =
8.4 Hz, 1H, Ar<bold>H</bold>), 8.36 (dd, <italic toggle="yes">J</italic> = 8.0
Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.49 (d, <italic toggle="yes">J</italic> = 1.3 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 21.3, 25.7, 26.3, 29.6, 53.3,
61.7, 126.6, 128.9, 132.4, 132.9, 141.7, 148.0, 165.1.</p><p>HRMS
calcd for C<sub>13</sub>H<sub>17</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 332.0621, found: 332.0615.</p></sec><sec id="sec5.1.38"><title>Methyl 4-(1-Naphthylsulfinyl)-3-sulfamoyl-benzoate (<bold>7m</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 47 mg, 60%, mp 125&#8211;127
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.93 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 7.61&#8211;7.68 (m, 4H, naphthyl-<bold>H</bold>), 8.04&#8211;8.08 (m, 1H, naphthyl-<bold>H</bold>), 8.11
(s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.14
(d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, naphthyl-<bold>H</bold>), 8.22
(d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.39 (dd, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.49&#8211;8.52 (m, 1H, naphthyl-<bold>H</bold>), 8.54 (d, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 53.4, 123.5, 125.5, 126.3, 127.5,
128.0, 128.7, 128.8, 129.2, 129.8, 132.5, 133.2, 133.8 (2C), 141.9,
143.1, 146.7, 165.0.</p><p>HRMS calcd for C<sub>18</sub>H<sub>15</sub>NO<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 390.0464, found:
390.0460.</p></sec><sec id="sec5.1.39"><title>4-(Benzenesulfinyl)-<italic toggle="yes">N</italic>-butyl-3-sulfamoyl-benzamide
(<bold>8a</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 61 mg, 80%, mp
168&#8211;171 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.89
(t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>),), 1.32 (sext, <italic toggle="yes">J</italic> = 7.8 Hz, 2H, NH&#173;(CH<sub>2</sub>)<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.50 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.27 (q, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.47&#8211;7.53 (m, 3H, Ar<bold>H</bold>), 7.75 (d, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, Ar<bold>H</bold>), 7.97 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.20 (s, 2H, Ar<bold>H</bold>), 8.35 (s, 1H, Ar<bold>H</bold>), 8.77 (t, <italic toggle="yes">J</italic> =
5.4 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.1, 20.1, 31.5, 39.6, 125.5,
126.4, 127.2, 129.8, 131.5, 131.7, 138.0, 142.0, 146.3, 147.3, 164.8.</p><p>HRMS calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 381.0937, found: 381.0933.</p></sec><sec id="sec5.1.40"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclohexylsulfinyl-3-sulfamoyl-benzamide
(<bold>8b</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 63 mg, 82%, mp
195&#8211;196 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.93
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.07&#8211;1.18 (m, 3H, C<bold>H</bold> cyclohexyl), 1.29&#8211;1.43
(m, 4H, C<bold>H</bold> cyclohexyl and C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.49&#8211;1.60 (m, 4H, C<bold>H</bold> cyclohexyl
and CH<sub>2</sub>
<bold>CH</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>2</sub>), 1.71&#8211;1.74 (m, 1H, C<bold>H</bold> cyclohexyl), 1.81&#8211;1.87
(m, 1H, C<bold>H</bold> cyclohexyl), 2.01&#8211;2.05 (m, 1H, C<bold>H</bold> cyclohexyl), 3.01 (tt, <italic toggle="yes">J</italic> = 12.3 Hz, <italic toggle="yes">J</italic> = 3.6 Hz, 1H, C<bold>H</bold>SO), 3.24&#8211;3.29 (m,
2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 7.84 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.02 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H, Ar<bold>H</bold>), 8.24 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.41
(d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.82 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 21.0, 25.1, 25.4,
26.1, 28.5, 31.6, 39.5, 60.9, 126.6, 127.9, 130.3, 137.7, 141.7, 143.8,
164.9.</p><p>HRMS calcd for C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 387.1407, found:
387.1401.</p></sec><sec id="sec5.1.41"><title>
<italic toggle="yes">N</italic>-Butyl-4-isopentylsulfinyl-3-sulfamoyl-benzamide
(<bold>8k</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 55 mg, 74%, mp
121&#8211;124 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.83
(d, <italic toggle="yes">J</italic> = 6.4 Hz, 6H, S&#173;(CH<sub>2</sub>)<sub>2</sub>CH&#173;(C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>)<sub>2</sub>), 0.92 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, NH&#173;(CH<sub>2</sub>)<sub>3</sub>C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.35 (sext, <italic toggle="yes">J</italic> = 7.2
Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 1.45&#8211;1.66 (m, 5H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>, SCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>C<bold>H</bold>), 3.31 (q, <italic toggle="yes">J</italic> = 6.8
Hz, 2H, NH<underline>C</underline>
<bold>H</bold>
<sub>
<underline>
<bold>2</bold>
</underline>
</sub>), 3.66&#8211;3.70 (m, 2H, SC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.33 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.25 (d, <italic toggle="yes">J</italic> = 8.0 Hz,
1H, Ar<bold>H</bold>), 8.30 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.60 (d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.96 (t, <italic toggle="yes">J</italic> = 5.6
Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C
NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.2, 20.1, 22.3, 27.0, 30.7,
31.5, 39.6, 53.4, 129.6, 131.5, 133.8, 138.1, 140.4, 143.1, 164.2.</p><p>HRMS calcd for C<sub>16</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 375.1407, found: 375.1411.</p></sec><sec id="sec5.1.42"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclopentylsulfinyl-3-sulfamoyl-benzamide
(<bold>8l</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 47 mg, 63%, mp
103&#8211;107 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.92
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.09&#8211;1.17 (m, 1H, C<bold>H</bold> cyclopentyl), 1.35
(sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NH&#173;(CH<sub>2</sub>)<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.45&#8211;1.63
(m, 6H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>,
C<bold>H</bold> cyclopentyl), 1.82&#8211;1.94 (m, 2H, C<bold>H</bold> cyclopentyl), 2.01&#8211;2.10 (m, 1H, C<bold>H</bold> cyclopentyl),
3.26&#8211;3.33 (m, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.52 (quint, <italic toggle="yes">J</italic> = 7.6 Hz, 1H, C<bold>H</bold> cyclopentyl),
7.85 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.07 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, Ar<bold>H</bold>), 8.23
(dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H,
Ar<bold>H</bold>), 8.39 (d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.80 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 21.4, 25.8, 26.3,
29.6, 31.5, 39.6, 61.7, 125.9, 127.7, 130.6, 137.7, 141.3, 145.4,
164.9.</p><p>HRMS calcd for C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 373.1250, found:
373.1255.</p></sec><sec id="sec5.1.43"><title>
<italic toggle="yes">N</italic>-Butyl-4-(1-naphthylsulfinyl)-3-sulfamoyl-benzamide
(<bold>8m</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 28 mg, 33%, mp
232&#8211;235 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.95
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.38 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NH&#173;(CH<sub>2</sub>)<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.56 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.28&#8211;3.37 (m, 2H,
NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.63&#8211;7.73 (m,
4H, naphthyl-<bold>H</bold>), 8.08 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.11&#8211;8.13 (m, 2H, naphthyl-<bold>H</bold>, Ar<bold>H</bold>), 8.18&#8211;8.22 (m, 1H, naphthyl-<bold>H</bold>), 8.26 (dd, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.47 (d, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, Ar<bold>H</bold>), 8.52&#8211;8.54 (m, 1H, naphthyl-<bold>H</bold>), 8.86 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 31.5, 39.6, 123.5,
125.3, 126.2, 127.4, 127.5, 128.0, 128.3, 129.2, 129.7, 131.5, 132.3,
133.8, 138.4, 142.0, 142.8, 144.3, 164.8.</p><p>HRMS calcd for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 431.1094, found: 431.1088.</p></sec><sec id="sec5.1.44"><title>General Procedure for the Syntheses of <bold>9&#173;(a&#8211;d, h,
i, l, m)</bold> and <bold>10&#173;(b, k&#8211;m)</bold>
</title><p>The 30%
H<sub>2</sub>O<sub>2</sub>(aq) (1.08 mmol, 0.110 mL) was added in
small portions over 3 h to a solution of appropriate methyl 4-sulfanilsubstituted-3-sulfamoyl-benzoate
(<bold>4a&#8211;d, h, i, l, m</bold>) or appropriate <italic toggle="yes">N</italic>-butyl-4-sulfanilsubstituted-3-sulfamoyl-benzamide (<bold>10b, k&#8211;m</bold>) (0.200 mmol) and acetic acid (2.0 mL) at 70 &#176;C and allowed
stirring for 6&#8211;8h. The solvent was removed under reduced pressure
and the resultant precipitate was filtered, and washed with H<sub>2</sub>O.</p></sec><sec id="sec5.1.45"><title>Methyl 4-(Benzenesulfonyl)-3-sulfamoyl-benzoate (<bold>9a</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 57 mg, 80%, mp 212&#8211;213
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.94 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.55 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.61 (t, <italic toggle="yes">J</italic> =
7.4 Hz, 2H, Ar<bold>H</bold>), 7.70 (t, <italic toggle="yes">J</italic> = 7.4 Hz,
1H, Ar<bold>H</bold>), 7.95 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H, Ar<bold>H</bold>), 8.43 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.61 (d, <italic toggle="yes">J</italic> = 8.2
Hz, 1H, Ar<bold>H</bold>), 8,64 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H,
Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 53.6,
128.4, 129.6, 130.7, 133.9,
134.3, 134.4, 135.1, 140.6, 141.6, 143.4, 164.5.</p><p>HRMS calcd
for C<sub>14</sub>H<sub>13</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 356.0257, found: 356.0266.</p></sec><sec id="sec5.1.46"><title>Methyl 4-Cyclohexylsulfonyl-3-sulfamoyl-benzoate (<bold>9b</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 61 mg, 85%, mp 155&#8211;156
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.17&#8211;1.81
(m, 10H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub> cyclohexyl), 3.86&#8211;3.91
(m, 1H, C<bold>H</bold>SO<sub>2</sub>), 3.95 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.42 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.25 (d, <italic toggle="yes">J</italic> = 8.1 Hz,
1H, Ar<bold>H</bold>), 8.42 (dd, <italic toggle="yes">J</italic> = 8.1 Hz, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>), 8.70 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; ppm: 24.8, 24.9, 25.1, 53.6, 61.8,
130.9, 133.6, 134.9, 135.2, 138.6, 143.8, 164.6.</p><p>HRMS calcd
for C<sub>14</sub>H<sub>19</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 362.0727, found: 362.0721.</p></sec><sec id="sec5.1.47"><title>Methyl 4-Benzylsulfonyl-3-sulfamoyl-benzoate (<bold>9c</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 66 mg, 89%, mp 189&#8211;190
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.94 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 5.03 (s, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>SO<sub>2</sub>), 7.19&#8211;7.21 (m, 2H,
Ar<bold>H</bold>), 7.30&#8211;7.34 (m, 3H, Ar<bold>H</bold>), 7.53
(s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.88
(d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.25 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.8 Hz, 1H, Ar<bold>H</bold>), 8.70 (d, <italic toggle="yes">J</italic> = 1.8 Hz, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 53.6, 60.9, 127.9, 129.0, 129.3,
130.6, 131.2, 133.4, 134.5, 135.1, 139.4, 143.7, 164.5.</p><p>HRMS
calcd for C<sub>15</sub>H<sub>15</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 370.0414, found: 370.0419.</p></sec><sec id="sec5.1.48"><title>Methyl 4-(2-Phenylethylsulfonyl)-3-sulfamoyl-benzoate (<bold>9d</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 64 mg, 83%, mp
186&#8211;187 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 2.98
(t, <italic toggle="yes">J</italic> = 8.0 Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>Ph), 3.94 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O),
4.02 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 2H,C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>SO<sub>2</sub>), 7.18&#8211;7.27 (m, 5H, Ar<bold>H</bold>), 7.44 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.30 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.40
(d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.67 (s, 1H,
Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 28.1,
53.6, 55.9, 127.1, 128.9,
129.0, 130.7, 133.9, 134.3, 135.1, 137.9, 140.0, 143.5, 164.5.</p><p>HRMS calcd for C<sub>16</sub>H<sub>17</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 384.0570, found: 384.0578.</p></sec><sec id="sec5.1.49"><title>Methyl 4-Methylsulfonyl-3-sulfamoyl-benzoate (<bold>9h</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 55 mg, 95%, mp 187&#8211;188
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.51 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>SO<sub>2</sub>), 3.96 (s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.42 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.36 (d, <italic toggle="yes">J</italic> =
8.2 Hz, 1H, Ar<bold>H</bold>), 8.45 (dd, <italic toggle="yes">J</italic> = 8.2
Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.67 (d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 44.1, 53.6, 130.5, 133.4, 134.1,
135.1, 141.6, 143.2, 164.6.</p><p>HRMS calcd for C<sub>9</sub>H<sub>11</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 294.0101,
found: 294.0106.</p></sec><sec id="sec5.1.50"><title>Methyl 4-Propylsulfonyl-3-sulfamoyl-benzoate (<bold>9i</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 57 mg, 88%, mp 169&#8211;170
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.94 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>CH<sub>2</sub>), 1.63&#8211;1.66 (m, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 3.66 (t, <italic toggle="yes">J</italic> = 7.7
Hz, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>SO<sub>2</sub>), 3.96
(s, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>O), 7.43 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.33 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H, Ar<bold>H</bold>), 8.44 (dd, <italic toggle="yes">J</italic> = 8.1 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.69
(d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 13.1, 16.2, 53.6, 56.7, 130.7,
133.9, 134.2, 135.2, 140.2, 143.5, 164.6.</p><p>HRMS calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 322.0414, found: 322.0422.</p></sec><sec id="sec5.1.51"><title>Methyl 4-Cyclopentylsulfonyl-3-sulfamoyl-benzoate (<bold>9l</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 5:1). Yield: 63 mg, 90%, mp 199&#8211;200
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 1.55&#8211;1.65
(m, 2H, C<bold>H</bold> cyclopentyl), 1.68&#8211;1.76 (m, 2H, C<bold>H</bold> cyclopentyl), 1.77&#8211;1.86 (m, 2H, C<bold>H</bold> cyclopentyl),
1.88&#8211;1.96 (m, 2H, C<bold>H</bold> cyclopentyl), 3.96 (s, 3H,
OC<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 4.44 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 1H, C<bold>H</bold> cyclopentyl), 7.41 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.34 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.42 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.70
(d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 26.0, 27.0, 53.6, 62.7, 130.9,
133.8, 134.6, 135.1, 139.7, 143.6, 164.6.</p><p>HRMS calcd for C<sub>13</sub>H<sub>17</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 348.0570, found: 348.0560.</p></sec><sec id="sec5.1.52"><title>Methyl 4-(1-Naphthylsulfonyl)-3-sulfamoyl-benzoate (<bold>9m</bold>)</title><p>The product was purified by flash chromatography on silica
gel (CHCl<sub>3</sub>:EtOAc, 8:1). Yield: 63 mg, 78%, mp 223&#8211;224
&#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 3.92 (s, 3H, OC<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 7.63&#8211;7.67 (m, 4H, naphthyl<bold>H</bold> and SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.74 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.12&#8211;8.14
(m, 1H, naphthyl<bold>H</bold>), 8.25 (d, <italic toggle="yes">J</italic> = 8.0
Hz, 1H, Ar<bold>H</bold>), 8.31&#8211;8.37 (m, 4H, naphthyl<bold>H</bold>), 8.70 (s, 1H, Ar<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 53.6, 123.9, 125.0, 127.5, 127.8,
129.1, 129.9, 130.8, 131.0, 133.0, 133.8, 134.2, 134.9, 135.2, 135.9,
141.8, 143.5, 164.5.</p><p>HRMS calcd for C<sub>18</sub>H<sub>15</sub>NO<sub>6</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 406.0414, found:
406.0423.</p></sec><sec id="sec5.1.53"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclohexylsulfonyl-3-sulfamoyl-benzamide
(<bold>10b</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 3:1). Yield: 68 mg, 84%, mp
155&#8211;156 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.93
(t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H, C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.17&#8211;1.81 (m, 14H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub> and
C<bold>H</bold> cyclohexyl), 3.30&#8211;3.32 (m, 2H, C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>NH), 3.90&#8211;3.93 (m, 1H, C<bold>H</bold>SO<sub>2</sub>), 7.33 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.19 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H, Ar<bold>H</bold>), 8.29 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H, Ar<bold>H</bold>), 8.61 (s, 1H, Ar<bold>H</bold>), 8.96 (t, <italic toggle="yes">J</italic> =
5.3 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
ppm: 14.1, 20.1, 24.9, 24.9, 25.1,
31.5, 39.6, 61.8, 129.8, 131.2, 134.4, 136.5, 140.4, 143.4, 164.2.</p><p>HRMS calcd for C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 403.1356, found: 403.1351.</p></sec><sec id="sec5.1.54"><title>
<italic toggle="yes">N</italic>-Butyl-4-isopentylsulfonyl-3-sulfamoyl-benzamide
(<bold>10k</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 53 mg, 68%, mp
160&#8211;162 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.83
(d, <italic toggle="yes">J</italic> = 6.4 Hz, 6H, S&#173;(CH<sub>2</sub>)<sub>2</sub>CH&#173;(C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>)<sub>
<bold>2</bold>
</sub>), 0.92 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 3H, NH&#173;(CH<sub>2</sub>)<sub>3</sub>C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.35 (sext, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 1.46&#8211;1.66 (m, 5H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>, SCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>C<bold>H</bold>), 3.31 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.66&#8211;3.70
(m, 2H, SC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.33 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.25 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, Ar<bold>H</bold>), 8.30 (dd, <italic toggle="yes">J</italic> = 8.0 Hz, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.60
(s, 1H, Ar<bold>H</bold>), 8.97 (t, <italic toggle="yes">J</italic> = 5.2 Hz, 1H,
N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2,
20.1, 22.3, 27.0, 30.7,
31.5, 39.7, 53.4, 129.6, 131.5, 133.8, 138.1, 140.4, 143.1, 164.2.</p><p>HRMS calcd for C<sub>16</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 391.1356, found: 391.1359.</p></sec><sec id="sec5.1.55"><title>
<italic toggle="yes">N</italic>-Butyl-4-cyclopentylsulfonyl-3-sulfamoyl-benzamide
(<bold>10l</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 57 mg, 73%, mp
143&#8211;145 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.92
(t, <italic toggle="yes">J</italic> = 7.6 Hz, 3H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.35 (sext, <italic toggle="yes">J</italic> = 7.6
Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.54 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 1.57&#8211;1.65
(m, 2H, C<bold>H</bold> cyclopentyl), 1.68&#8211;1.85 (m, 4H, C<bold>H</bold> cyclopentyl), 1.88&#8211;1.96 (m, 2H, C<bold>H</bold> cyclopentyl),
3.31 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 4.44 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 1H, SO<sub>2</sub>C<bold>H</bold> cyclopentyl), 7.32 (br. s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 8.26&#8211;8.31 (m, 2H,
Ar<bold>H</bold>), 8.62 (s, 1H, Ar<bold>H</bold>), 8.96 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.2, 20.1, 26.0, 27.0, 31.5,
39.6, 62.6, 129.7, 131.4, 134.1, 137.7, 140.3, 143.2, 164.2.</p><p>HRMS calcd for C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 389.1199, found: 389.1205.</p></sec><sec id="sec5.1.56"><title>
<italic toggle="yes">N</italic>-Butyl-4-(1-naphthylsulfonyl)-3-sulfamoyl-benzamide
(<bold>10m</bold>)</title><p>The product was purified by flash chromatography
on silica gel (CHCl<sub>3</sub>:EtOAc, 1:1). Yield: 22 mg, 24%, mp
266&#8211;268 &#176;C.</p><p>
<sup>
<bold>1</bold>
</sup>
<bold>H NMR</bold> (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 0.89
(t, <italic toggle="yes">J</italic> = 7.6 Hz, 3H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>3</bold>
</sub>), 1.32 (sext, <italic toggle="yes">J</italic> = 7.2
Hz, 2H, CH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>CH<sub>3</sub>), 1.51 (quint, <italic toggle="yes">J</italic> = 7.2 Hz, 2H, NHCH<sub>2</sub>C<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 3.29 (q, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, NHC<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.52 (s, 2H, SO<sub>2</sub>N<bold>H</bold>
<sub>
<bold>2</bold>
</sub>), 7.62&#8211;7.68 (m, 2H, naphthyl<bold>H</bold>), 7.74 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H, naphthyl<bold>H</bold>), 8.13&#8211;8.15
(m, 1H, naphthyl<bold>H</bold>), 8.19&#8211;8.23 (m, 2H, Ar<bold>H</bold>), 8.30 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H, naphthyl<bold>H</bold>), 8.34&#8211;8.39 (m, 2H, naphthyl<bold>H</bold>), 8.60
(d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H, Ar<bold>H</bold>), 8.92 (t, <italic toggle="yes">J</italic> = 5.2 Hz, 1H, N<bold>H</bold>).</p><p>
<sup>
<bold>13</bold>
</sup>
<bold>C NMR</bold> (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; ppm: 14.1, 20.1, 31.4, 39.6, 124.0,
125.0, 127.5, 127.8, 129.0, 129.8, 129.9, 130.7, 131.4, 132.7, 134.2,
135.5, 135.8, 139.8, 140.2, 143.1, 164.3.</p><p>HRMS calcd for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> [(M+H)<sup>+</sup>]: 447.1043, found: 447.1048.</p></sec></sec><sec id="sec5.2"><title>Protein Preparation</title><p>Recombinant human carbonic anhydrases
(CAI, CAII, CAIII, CAIV, CAVA, CAVB, CAVI, CAVII, CAIX, CAXII, CAXIII,
CAXIV) were expressed and chromatographically purified according to
previously published protocols<xref rid="ref47" ref-type="bibr"/> and were
used for FTSA experiments. Proteins (CAII and CAXIII) used for crystallization
were additionally purified by affinity chromatography and concentrated.
CAIX used for crystallization were expressed and purified according
to this protocol.<xref rid="ref48" ref-type="bibr"/> Production of recombinant
CAII and the extracellular part of CAIX comprising PG and CA domains
(residues 38&#8211;391) used in SFA experiments is described in ref <xref rid="ref49" ref-type="bibr" specific-use="ref-style=base-text"/>.</p></sec><sec id="sec5.3"><title>Determination of Observed Binding Parameters</title><sec id="sec5.3.1"><title>Fluorescent Thermal Shift Assay (FTSA)</title><p>Dissociation
constants, <italic toggle="yes">K</italic>
<sub>d,obs</sub>, (listed in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) of the compounds
binding to CAs were determined by the fluorescent thermal shift assay
using a QIAGEN&#8217;s real-time PCR cycler the &#8220;Rotor-Gene
Q&#8221; and Rotor-Gene Style 4-strip tubes from STARLAB. Ligands
were dissolved in DMSO stock solutions to concentrations of 10 mM
or 20 mM and used for the serial dilution of the dilution factor 2
in DMSO. These samples were diluted with buffer solution and mixed
with a prepared protein solution, consisting of protein stock, buffer
solution, and solvatochromic dye 8-anilino-1-naphthalenesulfonate
(ANS). All final samples typically contained up to 10 &#956;M CA,
compound solutions of serial dilution from 0 &#956;M to 200 &#956;M
at 8 different concentrations differing by 2 times, 50 &#956;M ANS,
50 mM sodium phosphate buffer at pH 7.0, 100 mM sodium chloride, and
2.0% (v/v) DMSO. Samples preparation is explained in detail in.<xref rid="ref50" ref-type="bibr"/> The excitation and emission wavelengths of ANS
were 365 &#177; 20 and 460 &#177; 15 nm. Samples were heated from
25 to 99 &#176;C at the rate of 1 &#176;C/min. The curve-fitting procedure
was performed by Thermott<xref rid="ref51" ref-type="bibr"/> at 37 &#176;C.
Data are deposited in the public database: Protein&#8211;Ligand Binding
Database<xref rid="ref52" ref-type="bibr"/> (Database URL: <uri xlink:href="https://plbd.org/">https://plbd.org/</uri>).</p></sec><sec id="sec5.3.2"><title>Stopped-Flow Carbon Dioxide Hydration Assay</title><p>Recombinant
CAII and the extracellular part of CAIX comprising PG and CA domains
(residues 38&#8211;391) were used in inhibition assays. A stopped-flow
instrument (BioLogic) was used for measuring the CA-catalyzed CO<sub>2</sub> hydration activity in the presence of inhibitors.<xref rid="ref53" ref-type="bibr"/> The assay buffer consisted of 0.2 mM Phenol
Red (pH indicator used in absorbance maximum of 557 nm), 20 mM HEPES
Na (pH 7.5), and 20 mM Na<sub>2</sub>SO<sub>4</sub>. The concentration
of CAII and CAIX in the enzyme assay was 4 nM and 1 nM, respectively.
To stabilize CAIX during the measurements, 0.0025% dodecyl-&#946;-D-maltopyranoside
(DDM, Anatrace, and Anagrade purity) was included in the reaction
mixture.</p><p>The substrate (CO<sub>2</sub>) concentration in the
reaction was 8.5 mM. Rates of the CA-catalyzed CO<sub>2</sub> hydration
reaction were followed for 30 s at 25 &#176;C. Four traces of substrate
conversion in the reaction were fitted by the exponential function
to determine the rate for each inhibitor concentration. The uncatalyzed
rates were determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitors (100 mM) were prepared
in dimethyl sulfoxide, and dilutions of up to 100 nM were made thereafter
in DMSO. Apparent <italic toggle="yes">K</italic>
<sub>i</sub>&#8217; values were
obtained from dose&#8211;response curves recorded for at least six
different concentrations of the test compound by the nonlinear least-squares
method using an Excel spreadsheet fitting the Williams-Morrison equation.<xref rid="ref54" ref-type="bibr"/>
<italic toggle="yes">K</italic>
<sub>i</sub> values were then
derived using the Cheng-Prusoff equation.<xref rid="ref55" ref-type="bibr"/> The <italic toggle="yes">K</italic>
<sub>m</sub> values used in the Cheng&#8211;Prusoff
equation were 9.3 mM for CAII and 7.5 mM for CAIX. Inhibition data
are provided in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>.</p></sec></sec><sec id="sec5.4"><title>Calculation of the Intrinsic Binding Parameters</title><p>The
detailed description of the importance and calculation of the intrinsic
values have been previously described.<xref rid="ref27" ref-type="bibr"/> For the calculation of the <italic toggle="yes">intrinsic</italic> dissociation
constants, the experimentally measured <italic toggle="yes">observed</italic> dissociation
constants determined by the FTSA, the p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide group of the compound, and the p<italic toggle="yes">K</italic>
<sub>a</sub> of the water molecule bound to the zinc cation by the
CA were used.</p><p>The intrinsic dissociation constant, <italic toggle="yes">K</italic>
<sub>d,int</sub>, is equal to<disp-formula id="eq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m001.jpg"/><mml:math id="d1e7716" display="block"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mi>int</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mi>obs</mml:mi></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msub><mml:mi>RSO</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msup><mml:mi>NH</mml:mi><mml:mo>&#8722;</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>CAZn</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub></mml:math></alternatives><label>1</label></disp-formula>
</p><p>The fraction of deprotonated
sulfonamide:<disp-formula id="eq2"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m002.jpg"/><mml:math id="d1e7759" display="block"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msub><mml:mi>RSO</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msup><mml:mi>NH</mml:mi><mml:mo>&#8722;</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>pH</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mo>,</mml:mo><mml:mi>SA</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>pH</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mo>,</mml:mo><mml:mi>SA</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></alternatives><label>2</label></disp-formula>
</p><p>The fraction of Zn&#173;(II)-bound
water form of CA:<disp-formula id="eq3"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m003.jpg"/><mml:math id="d1e7809" display="block"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>CAZn</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mo>,</mml:mo><mml:mi>CA</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>pH</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mo>,</mml:mo><mml:mi>CA</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>pH</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></alternatives><label>3</label></disp-formula>
<list list-type="bullet"><list-item><p>
<italic toggle="yes">K</italic>
<sub>d,obs</sub> &#8211; observed
dissociation constant;</p></list-item><list-item><p>
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m004.jpg"/><mml:math id="d1e7867" display="inline"><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">RSO</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi mathvariant="normal">NH</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></alternatives>
</inline-formula> and <inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m005.jpg"/><mml:math id="d1e7888" display="inline"><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">CAZn</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">H</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub></mml:math></alternatives>
</inline-formula> &#8211; fractions of deprotonated sulfonamide
and Zn&#173;(II)-bound water molecule;</p></list-item><list-item><p>
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c01421_m006.jpg"/><mml:math id="d1e7909" display="inline"><mml:mi mathvariant="normal">p</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mo>,</mml:mo><mml:mi>SA</mml:mi></mml:mrow></mml:msub></mml:math></alternatives>
</inline-formula> &#8211; p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide group;</p></list-item><list-item><p>p<italic toggle="yes">K</italic>
<sub>a,CA</sub> &#8211; p<italic toggle="yes">K</italic>
<sub>a</sub> value of water molecule bound to Zn&#173;(II) in
the active site of CA.</p></list-item></list>
</p><p>In this study, the pH value was equal to 7.0.</p><sec id="sec5.4.1"><title>Determination of p<italic toggle="yes">K</italic>
<sub>a</sub> Values of the
Compound Sulfonamide Group</title><p>The p<italic toggle="yes">K</italic>
<sub>a</sub> values of the water molecule bound to Zn<sup>2+</sup> in the active
site of CAs, p<italic toggle="yes">K</italic>
<sub>a,CA</sub>, were taken from ref <xref rid="ref42" ref-type="bibr" specific-use="ref-style=base-text"/> and of compounds, p<italic toggle="yes">K</italic>
<sub>a,SA</sub>, (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>)
were experimentally determined as described in ref <xref rid="ref56" ref-type="bibr" specific-use="ref-style=base-text"/>.</p><p>We used a constant
concentration of sulfonamide (25&#8211;400 &#956;M) and 2.0% (v/v)
or 20% (v/v; but only for very poorly soluble ones) of DMSO in universal
buffer (50 mM sodium acetate, 25 mM sodium borate, and 50 mM sodium
phosphate) at different pH values (in the range from pH 6.0 to 12.0
with 0.5 pH increment). UV/vis spectra of the compound solution were
recorded at 37 &#176;C using BMG Labtech CLARIOstarPlus plate reading
spectrophotometer. The p<italic toggle="yes">K</italic>
<sub>a</sub> values were
calculated by normalizing the absorbance and plotting it as a function
of pH, then fitting it to the Henderson&#8211;Hasselbalch equation
using the least-square method. The midpoint of this fitted curve is
equal to the sulfonamide group p<italic toggle="yes">K</italic>
<sub>a,SA</sub>.</p></sec></sec><sec id="sec5.5"><title>X-ray Crystallography</title><sec id="sec5.5.1"><title>Crystallization</title><p>Crystals of CAII, CAIX, and CAXIII
were obtained using the sitting-drop vapor diffusion method at room
temperature. <xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref> lists the concentrations of proteins and buffers used for crystallization.</p><table-wrap position="float" id="tbl4" orientation="portrait"><label>4</label><caption><title>Crystallization Conditions Used to
Grow Protein Crystals in This Study</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">
<bold>PDB ID</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>isozyme&#58872;compound</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>cystallization buffer</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>sitting drop</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">9FPT</td><td align="left" colspan="1" rowspan="1">CAII&#58872;<bold>2</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium bicine
(pH 9.0) and 2 M sodium malonate (pH 7.0)</td><td align="left" colspan="1" rowspan="1">2 &#956;L
of 41 mg/mL CAII solution and 2 &#956;L of crystallization
buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPU</td><td align="left" colspan="1" rowspan="1">CAII&#58872;<bold>3</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium bicine (pH 9.0) and 2 M sodium
malonate (pH 7.0)</td><td align="left" colspan="1" rowspan="1">2 &#956;L of 41 mg/mL CAII solution
and 2 &#956;L of crystallization
buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPQ</td><td align="left" colspan="1" rowspan="1">CAII&#58872;<bold>4c</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium bicine (pH 9.0), 0.2 M ammonium
sulfate, and 2
M sodium malonate (pH 7.0)</td><td align="left" colspan="1" rowspan="1">2 &#956;L of 41 mg/mL CAII
solution and 2.5 &#956;L of crystallization
buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPR</td><td align="left" colspan="1" rowspan="1">CAII&#58872;<bold>4d</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium bicine (pH 9.0), 0.2 M ammonium
sulfate, and 2
M sodium malonate (pH 7.0)</td><td align="left" colspan="1" rowspan="1">3 &#956;L of 12 mg/mL CAII
solution and 3 &#956;L of crystallization
buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPS</td><td align="left" colspan="1" rowspan="1">CAII&#58872;<bold>4h</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium bicine (pH 9.0) and 2 M sodium
malonate (pH 7.0)</td><td align="left" colspan="1" rowspan="1">3 &#956;L of 12 mg/mL CAII solution
and 3 &#956;L of crystallization
buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9R8X</td><td align="left" colspan="1" rowspan="1">CAIX&#58872;<bold>4d</bold>
</td><td align="left" colspan="1" rowspan="1">1.0 M diammonium hydrogen phosphate and 0.1
M sodium acetate
(pH 4.5)</td><td align="left" colspan="1" rowspan="1">10 mg/mL CAIX solution</td></tr><tr><td align="left" colspan="1" rowspan="1">9R8Y</td><td align="left" colspan="1" rowspan="1">CAIX&#58872;<bold>5b</bold>
</td><td align="left" colspan="1" rowspan="1">1.0
M diammonium hydrogen phosphate and 0.1 M sodium acetate
(pH 4.5)</td><td align="left" colspan="1" rowspan="1">10 mg/mL CAIX solution</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPV</td><td align="left" colspan="1" rowspan="1">CAXIII&#58872;<bold>4c</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium citrate (pH 5.5), 0.1 M sodium acetate
(pH 4.5),
and 26% of PEG4000</td><td align="left" colspan="1" rowspan="1">1 &#956;L of 23 mg/mL CAXIII solution
and 0.4 &#956;L of
crystallization buffer</td></tr><tr><td align="left" colspan="1" rowspan="1">9FPW</td><td align="left" colspan="1" rowspan="1">CAXIII&#58872;<bold>4d</bold>
</td><td align="left" colspan="1" rowspan="1">0.1 M sodium citrate
(pH 5.5), 0.1 M sodium acetate (pH 4.5),
and 26% of PEG4000</td><td align="left" colspan="1" rowspan="1">1 &#956;L of 23 mg/mL CAXIII solution
and 0.4 &#956;L of
crystallization buffer</td></tr></tbody></table></table-wrap></sec><sec id="sec5.5.2"><title>Ligand Soaking</title><p>The crystal structures of CAII and CAXIII
with ligands were obtained by soaking. A 50 mM solution of each ligand
was prepared in dimethyl sulfoxide. One &#956;L of this solution
was then diluted using 50 &#956;L of matching reservoir solution
corresponding to the conditions under which the crystal was formed.
Crystals were incubated for up to 1 week in the soaking solution.</p></sec><sec id="sec5.5.3"><title>Cocrystallization</title><p>The crystal structures of CAIX with
ligands were obtained by cocrystallization. <xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref> lists crystallization conditions. The ligand
used for cocrystallization was in 5&#8211;10 mM concentration, while
the stock solution contained 100 mM ligand dissolved in dimethyl sulfoxide.</p></sec><sec id="sec5.5.4"><title>Data Collection and Structure Determination</title><p>Data for
CAII and CAXII were collected at PETRA III BEAMLINE P13 (MX1) and
for CAIX at BESSY II beamline 14.1.</p><p>The data were processed
and scaled using XDS,<xref rid="ref58" ref-type="bibr"/> MOSFLM,<named-content content-type="bibref-group">
<xref rid="ref59" ref-type="bibr"/>,<xref rid="ref60" ref-type="bibr"/>
</named-content> and SCALA.<xref rid="ref61" ref-type="bibr"/> The crystal structures were
solved by molecular replacement using MOLREP.<xref rid="ref62" ref-type="bibr"/> The initial model for molecular replacement&#8211;CAII: 3HLJ; CAIX:
8Q18,<xref rid="ref63" ref-type="bibr"/> CAXIII: 2NNO. The structure was
refined by REFMAC<xref rid="ref64" ref-type="bibr"/> and remodeled using
COOT.<xref rid="ref57" ref-type="bibr"/> The 3D models of compounds were
constructed by the AVOGADRO<xref rid="ref65" ref-type="bibr"/> program and
ligand parameter files were created using LIBCHECK.<named-content content-type="bibref-group">
<xref rid="ref66" ref-type="bibr"/>,<xref rid="ref67" ref-type="bibr"/>
</named-content>
</p><p>The data diffraction and final model refinement statistics
and
PDB IDs are summarized in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>. All graphics were created using PyMOL Molecular Graphics
System. Authors will release the atomic coordinates upon article publication.</p></sec></sec><sec id="sec5.6"><title>Molecular Docking</title><p>The following receptors PDB IDs were
chosen for docking: CAII: 3HS4; CAIX: 6G9U, chain A; CAXIII: 4KNN,
chain A. The receptors selected from the Protein Data Bank differed
from the new X-ray structures presented in this Paper to decrease
bias. The proteins were prepared for docking using ChimeraX (version
1.9).<named-content content-type="bibref-group">
<xref rid="ref68" ref-type="bibr"/>&#8722;<xref rid="ref69" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref70" ref-type="bibr"/>
</named-content> The ligands were optimized using the MMFF94s force
field<named-content content-type="bibref-group">
<xref rid="ref71" ref-type="bibr"/>&#8722;<xref rid="ref72" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref73" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref74" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref75" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref76" ref-type="bibr"/>
</named-content> within Avogadro molecular viewer (version 1.2.0).<xref rid="ref65" ref-type="bibr"/> For series <bold>7</bold> ligands, two enantiomers of the
chiral sulfur were created and docked separately. The format conversions
were performed using OpenBabel (The Open Babel Package, version 3.1.1, <uri xlink:href="http://openbabel.org">http://openbabel.org</uri>).<xref rid="ref77" ref-type="bibr"/> The docking was performed using the Smina program
(version master:dc3dfab+).<xref rid="ref34" ref-type="bibr"/> Smina is based
on Autodock Vina.<xref rid="ref36" ref-type="bibr"/> The constrained optimization
was done using Smina, using a custom scoring function with a quadratic
bias function with weight <italic toggle="yes">w</italic>=&#8211;10 added to the
default Vina scoring function.<xref rid="ref36" ref-type="bibr"/> The quadratic
constraint forced sulfonamide nitrogen to adhere to its position in
the X-ray structure. A cubic docking box of size (24 &#197;),<xref rid="ref3" ref-type="bibr"/> exhaustiveness 100, and energy range 10 kcal/mol
was set as docking parameters. The resulting poses were rescored with
Smina using the Vinardo scoring function<xref rid="ref35" ref-type="bibr"/> without the constraint. Only one of the symmetry equivalent poses
(e.g., phenyl ring flip) was included when evaluating pose ranking
after docking. Heavy atom Root Mean Square Deviations (RMSD) were
calculated using DockRMSD software (version 1.1).<xref rid="ref78" ref-type="bibr"/>
</p><p>The quantum Density Functional Theory (DFT) optimizations
were performed using GAMESS-US (version 2019.R2)<xref rid="ref40" ref-type="bibr"/> using DFT functional &#969;B97X-D<xref rid="ref79" ref-type="bibr"/> with the cc-pVDZ basis set<named-content content-type="bibref-group">
<xref rid="ref80" ref-type="bibr"/>,<xref rid="ref81" ref-type="bibr"/>
</named-content> and the C-PCM implicit
solvation model for water.<xref rid="ref82" ref-type="bibr"/> The conformational
search was performed using CREST software (version 3.0.2)<xref rid="ref38" ref-type="bibr"/> using xTB (version 6.7.1)<xref rid="ref83" ref-type="bibr"/> computational engine, employing the GFN2-xTB semiempirical
tight binding method<xref rid="ref39" ref-type="bibr"/> and the ALPB implicit
solvation model for water.<xref rid="ref84" ref-type="bibr"/>
</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01421_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01421_si_002.csv" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>This research was supported by (i) a grant from
the Research Council of Lithuania (No. S-MIP-22-35); (ii) the National
Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102),
Funded by the European Union, Next Generation EU awarded to PR; and
(iii) the European Union&#8217;s Recovery and Resilience Mechanism
project (No.5.2.1.1.i.0/2/24/I/CFLA/001) &#8220;Consolidation of
the Latvian Institute of Organic Synthesis and the Latvian Biomedical
Research and Study Centre&#8221;. The authors also thank Martynas
Malik&#279;nas for performing HPLC analysis of compounds. We thank
Vilma Michailovien&#279;<sup>&#8224;</sup>, who died in 2022, for
performing numerous protein affinity purification procedures.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01421?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01421</ext-link>.<list list-type="simple" id="silist"><list-item><p>FTSA data of compound binding to CA isozymes; SFA data
of CA isozyme inhibition by compounds; determination of p<italic toggle="yes">K</italic>
<sub>a</sub> values of compound &#8211; RSO<sub>2</sub>NH<sub>2</sub>; NMR spectra of compounds; HPLC chromatograms of representative
compounds; ESI-MS spectra of representative compounds; and comparison
of docking and crystallographic binding poses (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>SMILE strings of the synthesized
compound and corresponding
biological activity: <italic toggle="yes">observed</italic> and <italic toggle="yes">intrinsic</italic> (<italic toggle="yes">K</italic>
<sub>d,obs</sub> and <italic toggle="yes">K</italic>
<sub>d,int</sub>) dissociation constants (in nM units) of investigated compounds
to all catalytically active human CAs at 37 &#176;C obtained by FTSA
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01421/suppl_file/jm5c01421_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item></list>
</p></notes><notes id="notes2" notes-type="author-contributions"><p>A.Z. and V.P.-L.
contributed equally to this paper.</p></notes><notes id="notes3" notes-type="conflict-of-interest"><p>The authors
declare the following competing financial interest(s): Authors declare
that they have patents and patent applications pending on CA inhibitors.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>CA</term><def><p>human
carbonic anhydrase</p></def></def-item><def-item><term>FTSA</term><def><p>fluorescent thermal
shift assay (or differential scanning fluorimetry DSF)</p></def></def-item><def-item><term>int</term><def><p>intrinsic</p></def></def-item><def-item><term>
<italic toggle="yes">K</italic>
<sub>d,int</sub>
</term><def><p>intrinsic equilibrium dissociation constant</p></def></def-item><def-item><term>
<italic toggle="yes">K</italic>
<sub>d,obs</sub>
</term><def><p>observed
equilibrium dissociation constant</p></def></def-item><def-item><term>obs</term><def><p>observed</p></def></def-item><def-item><term>p<italic toggle="yes">K</italic>
<sub>a,CA</sub>
</term><def><p>p<italic toggle="yes">K</italic>
<sub>a</sub> value of water molecule bound to Zn&#173;(II) in the active site of CA</p></def></def-item><def-item><term>p<italic toggle="yes">K</italic>
<sub>a,SA</sub>
</term><def><p>p<italic toggle="yes">K</italic>
<sub>a</sub> of the sulfonamide
group</p></def></def-item><def-item><term>SFA</term><def><p>stopped-flow
carbon dioxide hydration assay</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Whitesides</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Krishnamurthy</surname><given-names>V. M.</given-names></name><article-title>Designing ligands to bind proteins</article-title><source>Q. Rev. Biophys.</source><year>2005</year><volume>38</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1017/S0033583506004240</pub-id><pub-id pub-id-type="pmid">16817982</pub-id><pub-id pub-id-type="pmcid">PMC2712650</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Maren</surname><given-names>T. H.</given-names></name><article-title>Use of
inhibitors in physiological studies of carbonic anhydrase</article-title><source>Am. J. Physiol.-Ren. Physiol.</source><year>1977</year><volume>232</volume><fpage>F291</fpage><lpage>F297</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.1977.232.4.F291</pub-id><pub-id pub-id-type="pmid">403777</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Meldrum</surname><given-names>N. U.</given-names></name><name name-style="western"><surname>Roughton</surname><given-names>F. J.</given-names></name><article-title>Some properties
of carbonic anhydrase, the CO2 enzyme
present in blood</article-title><source>J. Physiol</source><year>1932</year><volume>75</volume><fpage>15P</fpage><lpage>16P</lpage></element-citation></ref><ref id="ref4"><mixed-citation publication-type="book" id="cit4"><source>The
Carbonic Anhydrases</source>; <publisher-name>Springer US</publisher-name>: <publisher-loc>Boston, MA</publisher-loc>, <year>1991</year>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="book" id="cit5"><source>The
Carbonic Anhydrases</source>; <publisher-name>Birkh&#228;user Basel</publisher-name>: <publisher-loc>Basel</publisher-loc>, <year>2000</year>.</mixed-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Krishnamurthy</surname><given-names>V. M.</given-names></name><etal/><article-title>Carbonic Anhydrase as a Model for Biophysical
and Physical-Organic
Studies of Proteins and Protein&#8211;Ligand Binding</article-title><source>Chem. Rev.</source><year>2008</year><volume>108</volume><fpage>946</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1021/cr050262p</pub-id><pub-id pub-id-type="pmid">18335973</pub-id><pub-id pub-id-type="pmcid">PMC2740730</pub-id></element-citation></ref><ref id="ref7"><mixed-citation publication-type="book" id="cit7"><source>The
Carbonic Anhydrases: Current and Emerging Therapeutic Targets</source>; <publisher-name>Springer International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2021</year>; Vol. <volume>75</volume>.</mixed-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Zamanova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shabana</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>U. K.</given-names></name><name name-style="western"><surname>Ilies</surname><given-names>M. A.</given-names></name><article-title>Carbonic anhydrases
as disease markers</article-title><source>Expert Opin. Ther. Pat.</source><year>2019</year><volume>29</volume><fpage>509</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1080/13543776.2019.1629419</pub-id><pub-id pub-id-type="pmid">31172829</pub-id><pub-id pub-id-type="pmcid">PMC6612586</pub-id></element-citation></ref><ref id="ref9"><mixed-citation publication-type="book" id="cit9"><source>Carbonic
Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial
Applications</source>; <publisher-name>Springer</publisher-name>: <publisher-loc>Netherlands, Dordrecht</publisher-loc>, <year>2014</year>; Vol. <volume>75</volume>.</mixed-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Abbate</surname><given-names>F.</given-names></name><etal/><article-title>Nonaromatic sulfonamide
group as an ideal anchor for potent human
carbonic anhydrase inhibitors: role of hydrogen-bonding networks in
ligand binding and drug design</article-title><source>J. Med. Chem.</source><year>2002</year><volume>45</volume><fpage>3583</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1021/jm011131t</pub-id><pub-id pub-id-type="pmid">12166931</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Martin</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Hann</surname><given-names>Z. S.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S. M.</given-names></name><article-title>Metalloprotein&#8211;Inhibitor
Binding:
Human Carbonic Anhydrase II as a Model for Probing Metal&#8211;Ligand
Interactions in a Metalloprotein Active Site</article-title><source>Inorg. Chem.</source><year>2013</year><volume>52</volume><fpage>12207</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1021/ic400295f</pub-id><pub-id pub-id-type="pmid">23706138</pub-id><pub-id pub-id-type="pmcid">PMC3781179</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Carta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Supuran</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Scozzafava</surname><given-names>A.</given-names></name><article-title>Sulfonamides
and their isosters as
carbonic anhydrase inhibitors</article-title><source>Future Med. Chem.</source><year>2014</year><volume>6</volume><fpage>1149</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.4155/fmc.14.68</pub-id><pub-id pub-id-type="pmid">25078135</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Fox</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Whitesides</surname><given-names>G. M.</given-names></name><article-title>The Molecular
Origin of Enthalpy/Entropy Compensation in Biomolecular Recognition</article-title><source>Annu. Rev. Biophys.</source><year>2018</year><volume>47</volume><fpage>223</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1146/annurev-biophys-070816-033743</pub-id><pub-id pub-id-type="pmid">29505727</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Aggarwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boone</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Kondeti</surname><given-names>B.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>R.</given-names></name><article-title>Structural annotation
of human carbonic anhydrases</article-title><source>J. Enzyme Inhib
Med. Chem.</source><year>2013</year><volume>28</volume><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.3109/14756366.2012.737323</pub-id><pub-id pub-id-type="pmid">23137351</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Supuran</surname><given-names>C. T.</given-names></name><article-title>Structure
and function of carbonic anhydrases</article-title><source>Biochem.
J.</source><year>2016</year><volume>473</volume><fpage>2023</fpage><lpage>2032</lpage><pub-id pub-id-type="doi">10.1042/BCJ20160115</pub-id><pub-id pub-id-type="pmid">27407171</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Lomelino</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Andring</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>R.</given-names></name><article-title>Crystallography and Its Impact on
Carbonic Anhydrase Research</article-title><source>Int. J. Med. Chem.</source><year>2018</year><volume>2018</volume><elocation-id>9419521</elocation-id><pub-id pub-id-type="doi">10.1155/2018/9419521</pub-id><pub-id pub-id-type="pmid">30302289</pub-id><pub-id pub-id-type="pmcid">PMC6158936</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Smirnovien&#279;</surname><given-names>J.</given-names></name><etal/><article-title>Switching the Inhibitor-Enzyme Recognition
Profile via Chimeric Carbonic
Anhydrase XII</article-title><source>ChemistryOpen</source><year>2021</year><volume>10</volume><fpage>567</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1002/open.202100042</pub-id><pub-id pub-id-type="pmid">33945229</pub-id><pub-id pub-id-type="pmcid">PMC8095314</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Scott</surname><given-names>A. D.</given-names></name><etal/><article-title>Thermodynamic Optimisation
in Drug Discovery: A Case Study using
Carbonic Anhydrase Inhibitors</article-title><source>ChemMedChem.</source><year>2009</year><volume>4</volume><fpage>1985</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.1002/cmdc.200900386</pub-id><pub-id pub-id-type="pmid">19882701</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Gl&#246;ckner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klebe</surname><given-names>G.</given-names></name><article-title>The Influence of Varying
Fluorination Patterns on the Thermodynamics and Kinetics of Benzenesulfonamide
Binding to Human Carbonic Anhydrase II</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><fpage>509</fpage><pub-id pub-id-type="doi">10.3390/biom10040509</pub-id><pub-id pub-id-type="pmid">32230853</pub-id><pub-id pub-id-type="pmcid">PMC7226267</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Zak&#353;auskas</surname><given-names>A.</given-names></name><etal/><article-title>Methyl 2-Halo-4-Substituted-5-Sulfamoyl-Benzoates
as High Affinity
and Selective Inhibitors of Carbonic Anhydrase IX</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>23</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.3390/ijms23010130</pub-id><pub-id pub-id-type="pmid">35008553</pub-id><pub-id pub-id-type="pmcid">PMC8745178</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Zak&#353;auskas</surname><given-names>A.</given-names></name><etal/><article-title>Design of two-tail compounds
with rotationally fixed benzenesulfonamide
ring as inhibitors of carbonic anhydrases</article-title><source>Eur.
J. Med. Chem.</source><year>2018</year><volume>156</volume><fpage>61</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.06.059</pub-id><pub-id pub-id-type="pmid">30006175</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Zak&#353;auskas</surname><given-names>A.</given-names></name><etal/><article-title>Halogenated and di-substituted benzenesulfonamides
as selective inhibitors
of carbonic anhydrase isoforms</article-title><source>Eur. J. Med.
Chem.</source><year>2020</year><volume>185</volume><elocation-id>111825</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.111825</pub-id><pub-id pub-id-type="pmid">31740053</pub-id></element-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><article-title>MERCAPTANS FROM THIOKETALS: CYCLODODECYL
MERCAPTAN</article-title>. <source>Org. Synth.</source><volume>61</volume>, <fpage>74</fpage> (<year>1983</year>).<pub-id pub-id-type="doi">10.15227/orgsyn.061.0074</pub-id></mixed-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Mahalingam</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Leamon</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Low</surname><given-names>P. S.</given-names></name><article-title>Carbonic Anhydrase
IX-Targeted Near-Infrared Dye for Fluorescence Imaging of Hypoxic
Tumors</article-title><source>Bioconjugate Chem.</source><year>2018</year><volume>29</volume><fpage>3320</fpage><lpage>3331</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00509</pub-id><pub-id pub-id-type="pmid">30185025</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Smirnovien&#279;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smirnovas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Matulis</surname><given-names>D.</given-names></name><article-title>Picomolar inhibitors of carbonic
anhydrase: Importance of inhibition and binding assays</article-title><source>Anal. Biochem.</source><year>2017</year><volume>522</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2017.01.022</pub-id><pub-id pub-id-type="pmid">28153585</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Taylor</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>King</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Burgen</surname><given-names>A. S. V.</given-names></name><article-title>Influence of
pH on the kinetics of
complex formation between aromatic sulfonamides and human carbonic
anhydrase</article-title><source>Biochemistry</source><year>1970</year><volume>9</volume><fpage>3894</fpage><lpage>3902</lpage><pub-id pub-id-type="doi">10.1021/bi00822a007</pub-id><pub-id pub-id-type="pmid">4993547</pub-id></element-citation></ref><ref id="ref27"><mixed-citation publication-type="book" id="cit27"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Zubrien&#279;</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Matulis</surname>, <given-names>D.</given-names></string-name></person-group><article-title>Observed
Versus Intrinsic Thermodynamics of Inhibitor Binding to Carbonic Anhydrases</article-title>. In <source>Carbonic Anhydrase as Drug Target: Thermodynamics and
Structure of Inhibitor Binding</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Matulis</surname>, <given-names>D.</given-names></string-name></person-group>, Ed.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2019</year>; pp <fpage>107</fpage>&#8211;<lpage>123</lpage>.</mixed-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Fisher</surname><given-names>S. Z.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kovalevsky</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>R.</given-names></name><article-title>Neutron Diffraction of Acetazolamide-Bound
Human Carbonic
Anhydrase II Reveals Atomic Details of Drug Binding</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>14726</fpage><lpage>14729</lpage><pub-id pub-id-type="doi">10.1021/ja3068098</pub-id><pub-id pub-id-type="pmid">22928733</pub-id><pub-id pub-id-type="pmcid">PMC3524527</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Aggarwal</surname><given-names>M.</given-names></name><etal/><article-title>Neutron structure of human carbonic anhydrase II in complex with
methazolamide: mapping the solvent and hydrogen-bonding patterns of
an effective clinical drug</article-title><source>IUCrJ.</source><year>2016</year><volume>3</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1107/S2052252516010514</pub-id><pub-id pub-id-type="pmid">28461893</pub-id><pub-id pub-id-type="pmcid">PMC5391854</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Zubrien&#279;</surname><given-names>A.</given-names></name><etal/><article-title>Intrinsic thermodynamics
of 4-substituted-2,3,5,6-tetrafluorobenzenesulfonamide
binding to carbonic anhydrases by isothermal titration calorimetry</article-title><source>Biophys Chem.</source><year>2015</year><volume>205</volume><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.bpc.2015.05.009</pub-id><pub-id pub-id-type="pmid">26079542</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Dudutien&#279;</surname><given-names>V.</given-names></name><etal/><article-title>Isoform-Selective Enzyme Inhibitors by
Exploring Pocket Size According
to the Lock-and-Key Principle</article-title><source>Biophys. J.</source><year>2020</year><volume>119</volume><fpage>1513</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2020.08.037</pub-id><pub-id pub-id-type="pmid">32971003</pub-id><pub-id pub-id-type="pmcid">PMC7642266</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Eisenberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Komaromy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>R.</given-names></name><article-title>Analysis of membrane
and surface protein sequences with the hydrophobic moment plot</article-title><source>J. Mol. Biol.</source><year>1984</year><volume>179</volume><fpage>125</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(84)90309-7</pub-id><pub-id pub-id-type="pmid">6502707</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Supuran</surname><given-names>C. T.</given-names></name><article-title>How many
carbonic anhydrase inhibition mechanisms exist?</article-title><source>J. Enzyme Inhib. Med. Chem.</source><year>2016</year><volume>31</volume><fpage>345</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.3109/14756366.2015.1122001</pub-id><pub-id pub-id-type="pmid">26619898</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Koes</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>C. J.</given-names></name><article-title>Lessons Learned
in Empirical Scoring
with smina from the CSAR 2011 Benchmarking Exercise</article-title><source>J. Chem. Inf. Model.</source><year>2013</year><volume>53</volume><fpage>1893</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1021/ci300604z</pub-id><pub-id pub-id-type="pmid">23379370</pub-id><pub-id pub-id-type="pmcid">PMC3726561</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Quiroga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>M. A.</given-names></name><article-title>Vinardo: A Scoring Function Based on Autodock Vina
Improves Scoring, Docking, and Virtual Screening</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><elocation-id>e0155183</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0155183</pub-id><pub-id pub-id-type="pmid">27171006</pub-id><pub-id pub-id-type="pmcid">PMC4865195</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Trott</surname><given-names>O.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name><article-title>AutoDock Vina: Improving the speed
and accuracy of
docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J. Comput. Chem.</source><year>2010</year><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id><pub-id pub-id-type="pmcid">PMC3041641</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>McNutt</surname><given-names>A. T.</given-names></name><etal/><article-title>GNINA 1.0: molecular docking with deep learning</article-title><source>J. Cheminf.</source><year>2021</year><volume>13</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13321-021-00522-2</pub-id><pub-id pub-id-type="pmcid">PMC8191141</pub-id><pub-id pub-id-type="pmid">34108002</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Pracht</surname><given-names>P.</given-names></name><etal/><article-title>CREST-A program for
the exploration of low-energy molecular chemical
space</article-title><source>J. Chem. Phys.</source><year>2024</year><volume>160</volume><fpage>114110</fpage><pub-id pub-id-type="doi">10.1063/5.0197592</pub-id><pub-id pub-id-type="pmid">38511658</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Bannwarth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ehlert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grimme</surname><given-names>S.</given-names></name><article-title>GFN2-xTB&#58872;An Accurate and Broadly
Parametrized Self-Consistent Tight-Binding Quantum Chemical Method
with Multipole Electrostatics and Density-Dependent Dispersion Contributions</article-title><source>J. Chem. Theory Comput.</source><year>2019</year><volume>15</volume><fpage>1652</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.8b01176</pub-id><pub-id pub-id-type="pmid">30741547</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Schmidt</surname><given-names>M. W.</given-names></name><etal/><article-title>General atomic and molecular electronic structure
system</article-title><source>J. Comput. Chem.</source><year>1993</year><volume>14</volume><fpage>1347</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1002/jcc.540141112</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Summa</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Langford</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Dinshaw</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rick</surname><given-names>S. W.</given-names></name><article-title>Calculations
of Absolute Free Energies, Enthalpies, and Entropies for Drug Binding</article-title><source>J. Chem. Theory Comput.</source><year>2024</year><volume>20</volume><fpage>2812</fpage><lpage>2819</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.4c00057</pub-id><pub-id pub-id-type="pmid">38538531</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Linkuvien&#279;</surname><given-names>V.</given-names></name><etal/><article-title>Thermodynamic, kinetic, and structural
parameterization of human
carbonic anhydrase interactions toward enhanced inhibitor design</article-title><source>Q. Rev. Biophys.</source><year>2018</year><volume>51</volume><elocation-id>e10</elocation-id><pub-id pub-id-type="doi">10.1017/S0033583518000082</pub-id><pub-id pub-id-type="pmid">30912486</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Baronas</surname><given-names>D.</given-names></name><etal/><article-title>Inhibitor binding to
metal-substituted metalloenzyme: Sulfonamide
affinity for carbonic anhydrase IX</article-title><source>J. Inorg.
Biochem.</source><year>2024</year><volume>256</volume><elocation-id>112547</elocation-id><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2024.112547</pub-id><pub-id pub-id-type="pmid">38581802</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Jackman</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Petrow</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>A. M.</given-names></name><article-title>Studies in the Field
of Diuretic Agents. Part VI Some Sulphamoylbenzoic Acids</article-title><source>J. Pharm. Pharmacol.</source><year>1962</year><volume>14</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1962.tb11158.x</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Jackman</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Petrow</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>A. M.</given-names></name><article-title>Studies in the Field
of Diuretic Agents</article-title><source>J. Pharm. Pharmacol.</source><year>1963</year><volume>15</volume><fpage>202</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1963.tb12772.x</pub-id><pub-id pub-id-type="pmid">13957185</pub-id></element-citation></ref><ref id="ref46"><mixed-citation publication-type="other" id="cit46"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Englert</surname>, <given-names>H. C.</given-names></string-name>; <string-name name-style="western"><surname>Lang</surname>, <given-names>H.-J.</given-names></string-name>; <string-name name-style="western"><surname>Linz</surname>, <given-names>W.</given-names></string-name>; <string-name name-style="western"><surname>Schoelkens</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western"><surname>Scholz</surname>, <given-names>W.</given-names></string-name></person-group><source>Benzoylguanidines, a
Process for Their Preparation, Their Use as Medicaments and Medicaments
Containing Them</source>; <year>1992</year>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Mickevi&#269;iu&#773;t&#279;</surname>, <given-names>A.</given-names></string-name></person-group><etal/><article-title>Recombinant Production of 12 Catalytically Active Human CA Isoforms</article-title>. In <source>Carbonic Anhydrase as Drug Target: Thermodynamics and
Structure of Inhibitor Binding</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Matulis</surname>, <given-names>D.</given-names></string-name></person-group>, Ed.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2019</year>; pp <fpage>15</fpage>&#8211;<lpage>37</lpage>.</mixed-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Leitans</surname><given-names>J.</given-names></name><etal/><article-title>Efficient Expression
and Crystallization System of Cancer-Associated
Carbonic Anhydrase Isoform IX</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>9004</fpage><lpage>9009</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01343</pub-id><pub-id pub-id-type="pmid">26522624</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Gr&#252;ner</surname><given-names>B.</given-names></name><etal/><article-title>Metallacarborane Sulfamides:
Unconventional, Specific, and Highly
Selective Inhibitors of Carbonic Anhydrase IX</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>9560</fpage><lpage>9575</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00945</pub-id><pub-id pub-id-type="pmid">31568723</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Kazlauskas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petrauskas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Paketuryt&#279;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Matulis</surname><given-names>D.</given-names></name><article-title>Standard operating
procedure for fluorescent thermal shift assay (FTSA) for determination
of protein&#8211;ligand binding and protein stability</article-title><source>Eur. Biophys. J.</source><year>2021</year><volume>50</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1007/s00249-021-01537-1</pub-id><pub-id pub-id-type="pmid">33914114</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Gedgaudas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baronas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kazlauskas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petrauskas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Matulis</surname><given-names>D.</given-names></name><article-title>Thermott: A comprehensive online
tool for protein&#8211;ligand
binding constant determination</article-title><source>Drug Discovery
Today</source><year>2022</year><volume>27</volume><fpage>2076</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2022.05.008</pub-id><pub-id pub-id-type="pmid">35577233</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Ling&#279;</surname><given-names>D.</given-names></name><etal/><article-title>PLBD: protein&#8211;ligand binding database of thermodynamic and
kinetic intrinsic parameters</article-title><source>Database</source><year>2023</year><volume>2023</volume><fpage>baad040</fpage><pub-id pub-id-type="doi">10.1093/database/baad040</pub-id><pub-id pub-id-type="pmid">37290059</pub-id><pub-id pub-id-type="pmcid">PMC10250011</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Khalifah</surname><given-names>R. G.</given-names></name><article-title>The carbon
dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic
studies on the native human isoenzymes B and C</article-title><source>J. Biol. Chem.</source><year>1971</year><volume>246</volume><fpage>2561</fpage><lpage>2573</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)62326-9</pub-id><pub-id pub-id-type="pmid">4994926</pub-id></element-citation></ref><ref id="ref54"><mixed-citation publication-type="book" id="cit54"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Williams</surname>, <given-names>J. W.</given-names></string-name>; <string-name name-style="western"><surname>Morrison</surname>, <given-names>J. F.</given-names></string-name></person-group><article-title>The kinetics
of reversible tight-binding inhibition</article-title>. In <source>Methods in Enzymology</source>; <publisher-name>Academic Press</publisher-name>: <year>1979</year>; Vol. <volume>63</volume>, pp <fpage>437</fpage>&#8211;<lpage>467</lpage>.<pub-id pub-id-type="pmid">502865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0076-6879(79)63019-7</pub-id></mixed-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Cheng</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Prusoff</surname><given-names>W. H.</given-names></name><article-title>Relationship between the inhibition constant (Ki) and
the concentration of inhibitor which causes 50% inhibition (I50) of
an enzymatic reaction</article-title><source>Biochem. Pharmacol.</source><year>1973</year><volume>22</volume><fpage>3099</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(73)90196-2</pub-id><pub-id pub-id-type="pmid">4202581</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Snyder</surname><given-names>P. W.</given-names></name><etal/><article-title>Mechanism of the hydrophobic
effect in the biomolecular recognition
of arylsulfonamides by carbonic anhydrase</article-title><source>Proc.
Natl. Acad. Sci. U. S. A.</source><year>2011</year><volume>108</volume><fpage>17889</fpage><lpage>17894</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114107108</pub-id><pub-id pub-id-type="pmid">22011572</pub-id><pub-id pub-id-type="pmcid">PMC3207675</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Emsley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cowtan</surname><given-names>K.</given-names></name><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallogr. Biol. Crystallogr.</source><year>2004</year><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Kabsch</surname><given-names>W.</given-names></name><article-title>XDS</article-title><source>Acta Crystallogr.
Sect. D</source><year>2010</year><volume>D66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmcid">PMC2815665</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Battye</surname><given-names>T. G. G.</given-names></name><name name-style="western"><surname>Kontogiannis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>A. G. W.</given-names></name><article-title>iMOSFLM:
a new graphical interface for diffraction-image processing with MOSFLM</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><year>2011</year><volume>67</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1107/S0907444910048675</pub-id><pub-id pub-id-type="pmid">21460445</pub-id><pub-id pub-id-type="pmcid">PMC3069742</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Leslie</surname><given-names>A. G. W.</given-names></name><article-title>The
integration of macromolecular diffraction data</article-title><source>Acta Crystallogr. Biol. Crystallogr.</source><year>2006</year><volume>62</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1107/S0907444905039107</pub-id><pub-id pub-id-type="pmid">16369093</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Evans</surname><given-names>P.</given-names></name><article-title>Scaling and
assessment of data quality</article-title><source>Acta Crystallogr.
D Biol. Crystallogr.</source><year>2006</year><volume>62</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1107/S0907444905036693</pub-id><pub-id pub-id-type="pmid">16369096</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Vagin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teplyakov</surname><given-names>A.</given-names></name><article-title>MOLREP: an Automated Program for
Molecular Replacement</article-title><source>J. Appl. Crystallogr.</source><year>1997</year><volume>30</volume><fpage>1022</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1107/S0021889897006766</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Leitans</surname><given-names>J.</given-names></name><etal/><article-title>Structural Basis of
Saccharin Derivative Inhibition of Carbonic Anhydrase
IX</article-title><source>ChemMedChem</source><year>2023</year><volume>18</volume><elocation-id>e202300454</elocation-id><pub-id pub-id-type="doi">10.1002/cmdc.202300454</pub-id><pub-id pub-id-type="pmid">37837260</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Murshudov</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Vagin</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>E. J.</given-names></name><article-title>Refinement of macromolecular structures
by the maximum-likelihood method</article-title><source>Acta Crystallogr.
Biol. Crystallogr.</source><year>1997</year><volume>53</volume><fpage>240</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1107/S0907444996012255</pub-id><pub-id pub-id-type="pmid">15299926</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Hanwell</surname><given-names>M. D.</given-names></name><etal/><article-title>Avogadro: An advanced semantic chemical editor,
visualization, and
analysis platform</article-title><source>J. Cheminf.</source><year>2012</year><volume>4</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-4-17</pub-id><pub-id pub-id-type="pmcid">PMC3542060</pub-id><pub-id pub-id-type="pmid">22889332</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Vagin</surname><given-names>A. A.</given-names></name><etal/><article-title>REFMAC5 dictionary: organization of prior chemical knowledge and
guidelines for its use</article-title><source>Acta Crystallogr. Biol.
Crystallogr.</source><year>2004</year><volume>60</volume><fpage>2184</fpage><lpage>2195</lpage><pub-id pub-id-type="doi">10.1107/S0907444904023510</pub-id><pub-id pub-id-type="pmid">15572771</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Lebedev</surname><given-names>A. A.</given-names></name><etal/><article-title>JLigand: a graphical tool for the CCP4 template-restraint library</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><year>2012</year><volume>68</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1107/S090744491200251X</pub-id><pub-id pub-id-type="pmid">22505263</pub-id><pub-id pub-id-type="pmcid">PMC3322602</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Meng</surname><given-names>E. C.</given-names></name><etal/><article-title>UCSF C<sc>himera</sc>X: Tools for structure building and analysis</article-title><source>Protein Sci.</source><year>2023</year><volume>32</volume><elocation-id>e4792</elocation-id><pub-id pub-id-type="doi">10.1002/pro.4792</pub-id><pub-id pub-id-type="pmid">37774136</pub-id><pub-id pub-id-type="pmcid">PMC10588335</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Pettersen</surname><given-names>E. F.</given-names></name><etal/><article-title>UCSF ChimeraX: Structure
visualization for researchers, educators,
and developers</article-title><source>Protein Sci. Publ. Protein Soc.</source><year>2021</year><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmcid">PMC7737788</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Goddard</surname><given-names>T. D.</given-names></name><etal/><article-title>UCSF ChimeraX: Meeting
modern challenges in visualization and analysis</article-title><source>Protein Sci. Publ. Protein Soc.</source><year>2018</year><volume>27</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/pro.3235</pub-id><pub-id pub-id-type="pmcid">PMC5734306</pub-id><pub-id pub-id-type="pmid">28710774</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>Merck molecular
force field. I. Basis, form, scope, parameterization, and performance
of MMFF94</article-title><source>J. Comput. Chem.</source><year>1996</year><volume>17</volume><fpage>490</fpage><lpage>519</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199604)17:5/6&amp;#x0003c;490::AID-JCC1&amp;#x0003e;3.0.CO;2-P</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>Merck molecular
force field. II. MMFF94 van der Waals and electrostatic parameters
for intermolecular interactions</article-title><source>J. Comput.
Chem.</source><year>1996</year><volume>17</volume><fpage>520</fpage><lpage>552</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199604)17:5/6&amp;#x0003c;520::AID-JCC2&amp;#x0003e;3.0.CO;2-W</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>Merck molecular
force field. III. Molecular geometries and vibrational frequencies
for MMFF94</article-title><source>J. Comput. Chem.</source><year>1996</year><volume>17</volume><fpage>553</fpage><lpage>586</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199604)17:5/6&amp;#x0003c;553::AID-JCC3&amp;#x0003e;3.0.CO;2-T</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Nachbar</surname><given-names>R. B.</given-names></name><article-title>Merck molecular
force field. IV. conformational energies
and geometries for MMFF94</article-title><source>J. Comput. Chem.</source><year>1996</year><volume>17</volume><fpage>587</fpage><lpage>615</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199604)17:5/6&amp;#x0003c;587::AID-JCC4&amp;#x0003e;3.0.CO;2-Q</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>Merck molecular
force field. V. Extension of MMFF94 using experimental data, additional
computational data, and empirical rules</article-title><source>J.
Comput. Chem.</source><year>1996</year><volume>17</volume><fpage>616</fpage><lpage>641</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199604)17:5/6&amp;#x0003c;616::AID-JCC5&amp;#x0003e;3.0.CO;2-X</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>MMFF VI.
MMFF94s option for energy minimization studies</article-title><source>J. Comput. Chem.</source><year>1999</year><volume>20</volume><fpage>720</fpage><lpage>729</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199905)20:7&amp;#x0003c;720::AID-JCC7&amp;#x0003e;3.0.CO;2-X</pub-id><pub-id pub-id-type="pmid">34376030</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>O&#8217;Boyle</surname><given-names>N. M.</given-names></name><etal/><article-title>Open Babel: An open
chemical toolbox</article-title><source>J. Cheminf.</source><year>2011</year><volume>3</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id><pub-id pub-id-type="pmcid">PMC3198950</pub-id><pub-id pub-id-type="pmid">21982300</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Bell</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><article-title>DockRMSD: an open-source tool for atom mapping and RMSD calculation
of symmetric molecules through graph isomorphism</article-title><source>J. Cheminf.</source><year>2019</year><volume>11</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s13321-019-0362-7</pub-id><pub-id pub-id-type="pmcid">PMC6556049</pub-id><pub-id pub-id-type="pmid">31175455</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Chai</surname><given-names>J.-D.</given-names></name><name name-style="western"><surname>Head-Gordon</surname><given-names>M.</given-names></name><article-title>Long-range
corrected hybrid density functionals with
damped atom&#8211;atom dispersion corrections</article-title><source>Phys. Chem. Chem. Phys.</source><year>2008</year><volume>10</volume><fpage>6615</fpage><lpage>6620</lpage><pub-id pub-id-type="doi">10.1039/b810189b</pub-id><pub-id pub-id-type="pmid">18989472</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Dunning</surname><given-names>T. H.</given-names></name><article-title>Gaussian
basis sets for use in correlated molecular calculations. I. The atoms
boron through neon and hydrogen</article-title><source>J. Chem. Phys.</source><year>1989</year><volume>90</volume><fpage>1007</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1063/1.456153</pub-id></element-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Woon</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Dunning</surname><given-names>T. H.</given-names><suffix>Jr.</suffix></name><article-title>Gaussian basis sets for use in correlated
molecular calculations. III. The atoms aluminum through argon</article-title><source>J. Chem. Phys.</source><year>1993</year><volume>98</volume><fpage>1358</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1063/1.464303</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Barone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cossi</surname><given-names>M.</given-names></name><article-title>Quantum Calculation of Molecular Energies and Energy Gradients in
Solution by a Conductor Solvent Model</article-title><source>J. Phys.
Chem. A</source><year>1998</year><volume>102</volume><fpage>1995</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1021/jp9716997</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Bannwarth</surname><given-names>C.</given-names></name><etal/><article-title>Extended
tight-binding quantum chemistry methods</article-title><source>Wiley
Interdiscip. Rev.: Comput. Mol. Sci.</source><year>2021</year><volume>11</volume><elocation-id>e1493</elocation-id><pub-id pub-id-type="doi">10.1002/wcms.1493</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Ehlert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spicher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grimme</surname><given-names>S.</given-names></name><article-title>Robust and Efficient
Implicit Solvation Model for Fast Semiempirical Methods</article-title><source>J. Chem. Theory Comput.</source><year>2021</year><volume>17</volume><fpage>4250</fpage><lpage>4261</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.1c00471</pub-id><pub-id pub-id-type="pmid">34185531</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>